| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
Register now or login to post to this thread.
Glaxo trading near low (GSK)
tobyboy - 01 Aug 2007 09:25
there seems to be some heavy resistance around these level with a lot of potential upside.
tobyboy - 01 Aug 2007 10:54 - 2 of 290
its on steriods today trading up
tobyboy - 01 Aug 2007 10:55 - 3 of 290
cpeck12 - 09 Nov 2007 08:22 - 4 of 290
Any comment on this one? Their vaccines seem to generate good profit and growth potential.
Greyhound - 09 Nov 2007 08:54 - 5 of 290
It's been low and unpopular for years. I like the stock but unconvinced it is yet time to buy, however good long term hold. The sector will come back into favour and I'm pleased with the new CEO appointment.
Falcothou - 09 Nov 2007 08:59 - 6 of 290
I think the low dollar is really affecting earnings, there is a lot of uncertainty with Avandia and the associated legal issues but it has been hammered and is tempting but perhaps whern the dollar bounces back will be the time to buy
Greyhound - 09 Nov 2007 09:05 - 7 of 290
Quite agree falco. Then it will be dirt cheap and will get back to the old levels over 22. Incredible to think I sold stock up there years ago, but had held through the Girolami and Sir Richard years - ie. a long time!
cpeck12 - 09 Nov 2007 09:13 - 8 of 290
Agree with Greyhound, Andrew Witty is way better positioned to capture Asia's growth.
cpeck12 - 09 Nov 2007 15:27 - 9 of 290
Holding up pretty well. Not bad for income I think.
halifax - 09 Nov 2007 17:24 - 10 of 290
If you want income buy UK banks now!
cpeck12 - 13 Nov 2007 13:55 - 11 of 290
Seems like good value to me like I said earlier. Anyone?
cpeck12 - 13 Nov 2007 15:05 - 12 of 290
And for those who are still concern with Avandia, it is not that bad after all. See:
http://www.reuters.com/article/health-SP/idUSL1214902720071113
http://www.reuters.com/article/health-SP/idUSL1214902720071113
Greyhound - 13 Nov 2007 15:09 - 13 of 290
It's the pipeline and the dollar effect that is causing the lacklustre performance imo.
cpeck12 - 13 Nov 2007 15:37 - 14 of 290
Thought GSK has got one of the largest pipeline?
Greyhound - 14 Nov 2007 17:51 - 15 of 290
Promising update on Avandia just out for you...
cpeck12 - 15 Nov 2007 08:39 - 16 of 290
Avandia is going to have similar recovery play as Crestor if not better, I suspect. Btw, Asia type 2 diabetes is now growing at an alarming rate. GSK will be able to take advantage on these markets with Andrew on the CEO role.
cpeck12 - 15 Nov 2007 13:24 - 17 of 290
Pound took a turn at 2.11 last friday due to widening trade deficit. Suspect that's the peak. So, this share could be better than putting money in the bank.
cpeck12 - 22 Nov 2007 10:19 - 18 of 290
Took a turn today after a few broker recommendations. Still cheap IMO.
Greyhound - 22 Nov 2007 10:24 - 19 of 290
Personally I think you won't see that much of a stronger dollar until 2009. FX markets always overrun too.
cpeck12 - 03 Dec 2007 08:13 - 20 of 290
And this is what I call a great company! See below:
Glaxo to offer 2 mln stg packages, board seats to Viehbacher, Stout - report
AFX
LONDON (Thomson Financial) - Pharmaceutical giant GlaxoSmithKline is to offer 2 mln stg retention packages and seats on the board to Chris Viehbacher and David Stout, who missed out on becoming chief executive, an effort to keep them at the company, the Sunday Times reported without citing sources.
Viehbacher, who runs the group's US pharmaceuticals division, and David Stout, the president of pharmaceutical operations, missed out on the CEO's job when Andrew Witty was appointed to lead the group two months ago.
The group, the paper reported, has told investors that the share packages will be handed out to Viehbacher and Stout over the next two to three years. There will also be a small cash payment, the paper reported, without giving details.
alexander.ferguson@thomson.com
Glaxo to offer 2 mln stg packages, board seats to Viehbacher, Stout - report
AFX
LONDON (Thomson Financial) - Pharmaceutical giant GlaxoSmithKline is to offer 2 mln stg retention packages and seats on the board to Chris Viehbacher and David Stout, who missed out on becoming chief executive, an effort to keep them at the company, the Sunday Times reported without citing sources.
Viehbacher, who runs the group's US pharmaceuticals division, and David Stout, the president of pharmaceutical operations, missed out on the CEO's job when Andrew Witty was appointed to lead the group two months ago.
The group, the paper reported, has told investors that the share packages will be handed out to Viehbacher and Stout over the next two to three years. There will also be a small cash payment, the paper reported, without giving details.
alexander.ferguson@thomson.com
greekman
- 08 Jan 2008 07:48
- 21 of 290
FDA Approves 19 New U.S. Drugs, Fewest Since '83; Glaxo Leads
By Justin Blum
Jan. 8 (Bloomberg) -- The U.S. Food and Drug Administration approved 19 new drugs in 2007, the fewest in 24 years, after drugmakers focused on developing uses for existing products.
"The hurdle has been raised, there is no question about it,'' said Jean-Pierre Garnier, Glaxo's chief executive officer, in an Oct. 24 conference call with analysts. ``We are working on 25 launches over the next three years. Some of them will be delayed that probably wouldn't have been delayed if we had those 25 products even two years ago.''
http://www.bloomberg.com/apps/news?pid=20601087&sid=a2MOCNVDHucs&refer=home
END of Report.
As to the bribery issue it appears that 2,200 companies from some 40 countries are suspected of colluding with Saddam's regime to bilk the humanitarian program of $1.8 billion.
Anyone who believes anything will come of any investigation with so many companies involved is IMHO living in dream land.
I would think the number of companies that went down the legal moral route are far less than those who didn't.
The bottom line is that to get any sort of deal with a corrupt country (and there are very few that are not) bribery is often a companies best bargaining chip. On a lesser scale if you want to deal with so called none corrupt countries it's called incentives, corruption by a lesser name.
The Authorities will make a lot of noise and spend a lot of our money, then everything will just fade away.
Cynicism rules.
By Justin Blum
Jan. 8 (Bloomberg) -- The U.S. Food and Drug Administration approved 19 new drugs in 2007, the fewest in 24 years, after drugmakers focused on developing uses for existing products.
"The hurdle has been raised, there is no question about it,'' said Jean-Pierre Garnier, Glaxo's chief executive officer, in an Oct. 24 conference call with analysts. ``We are working on 25 launches over the next three years. Some of them will be delayed that probably wouldn't have been delayed if we had those 25 products even two years ago.''
http://www.bloomberg.com/apps/news?pid=20601087&sid=a2MOCNVDHucs&refer=home
END of Report.
As to the bribery issue it appears that 2,200 companies from some 40 countries are suspected of colluding with Saddam's regime to bilk the humanitarian program of $1.8 billion.
Anyone who believes anything will come of any investigation with so many companies involved is IMHO living in dream land.
I would think the number of companies that went down the legal moral route are far less than those who didn't.
The bottom line is that to get any sort of deal with a corrupt country (and there are very few that are not) bribery is often a companies best bargaining chip. On a lesser scale if you want to deal with so called none corrupt countries it's called incentives, corruption by a lesser name.
The Authorities will make a lot of noise and spend a lot of our money, then everything will just fade away.
Cynicism rules.
cpeck12 - 01 Feb 2008 09:20 - 22 of 290
Looks like a base is formed and we're heading for a bounce. A good share in difficult times like now.
Falcothou - 01 Feb 2008 10:06 - 23 of 290
Might be worth puuting a limit order in for 1150, it seems a good support and was hit yesterday
Guscavalier
- 01 Feb 2008 20:45
- 24 of 290
Glaxo has around 30 drugs in the later stages of development which may hopefully counter worries about patent expiries. Glaxo is also a major US$ earner and may improve earnings in Sterling terms should the latter weaken against the US$ this year. Yield should be solid 4%+ at current sp of 1184p
cpeck12 - 07 Feb 2008 11:59 - 25 of 290
The base is now much clearer. Anyone in the party? Maybe not..
Greyhound - 07 Feb 2008 16:34 - 26 of 290
Not a good picture of health imo.
Falcothou - 15 Feb 2008 13:51 - 27 of 290
LONDON (Thomson Financial) - US billionaire Warren Buffett has invested significantly in European pharmaceutical majors GlaxoSmithKline and Sanofi-Aventis, a filing to the US Securities and Exchange Commission has revealed.
As of December 31, Buffett, through his holding company Berkshire Hathaway, owned 1.51 mln American Depository Receipts of Glaxo, valued at 76.1 mln usd, and 3.6 mln ADRs of Sanofi-Aventis, valued at 162.5 mln usd.
Since January 2, Glaxo has issued a profit warning and its shares have fallen 11.5 pct from 1,270 pence to 1,124 pence by 9.26 am today.
Shares in Sanofi-Aventis have slid by 14.7 pct from 62.28 eur on January 2, to 53.1 eur at 9.32 am today.
The trades, however, represent a very small part of Buffett's total investments, worth a total of 68.8 bln usd, for the three months ending Dec 31 that are covered by the filing.
Investments included a stake worth 7.9 bln usd in American Express and 4.1 bln usd holding in Johnson & Johnson.
As of December 31, Buffett, through his holding company Berkshire Hathaway, owned 1.51 mln American Depository Receipts of Glaxo, valued at 76.1 mln usd, and 3.6 mln ADRs of Sanofi-Aventis, valued at 162.5 mln usd.
Since January 2, Glaxo has issued a profit warning and its shares have fallen 11.5 pct from 1,270 pence to 1,124 pence by 9.26 am today.
Shares in Sanofi-Aventis have slid by 14.7 pct from 62.28 eur on January 2, to 53.1 eur at 9.32 am today.
The trades, however, represent a very small part of Buffett's total investments, worth a total of 68.8 bln usd, for the three months ending Dec 31 that are covered by the filing.
Investments included a stake worth 7.9 bln usd in American Express and 4.1 bln usd holding in Johnson & Johnson.
greekman
- 22 Feb 2008 17:08
- 28 of 290
Strange re the drop today. I would have thought the news was far more positive than negative. 15 mill buy just gone through. No doubt an RNS will be forthcoming.
Guscavalier
- 23 Feb 2008 08:33
- 29 of 290
probably a general reaction to weakness of Wall Street
Falcothou - 23 Feb 2008 08:41 - 30 of 290
Could possibly be part of a buyback Greekman or reaction to further anticipated dollar weakness, though a good share to accumulate on any weakness
Falcothou - 06 Mar 2008 08:40 - 31 of 290
Probably foolish but just bought some of these. If they're good enough for Buffett....
partridge
- 06 Mar 2008 11:14
- 32 of 290
You and me both.Incredible cash generator and yield well over 4% - happy to suffer some short term volatility for medium term gain...at least that is the theory.
Greyhound - 06 Mar 2008 16:54 - 33 of 290
I'd like to see us test the 10 again and then may be tempted to jump in. The beast is so large it takes a long time to change course and steer in a favourably direction. The times for pharms is coming again however. Just as EUR/USD hits new highs today nearing 1.54 it won't be long before the dollar will come back and kick ass. Then you've got a winner here with a strong dollar earner.
greekman
- 01 Apr 2008 08:35
- 34 of 290
Glaxo
ING Wholesale Banking has rated Europe's largest drugmaker a buy in new coverage saying the company may benefit from the appointment of Andrew Witty as chief executive officer.
ING Wholesale Banking has rated Europe's largest drugmaker a buy in new coverage saying the company may benefit from the appointment of Andrew Witty as chief executive officer.
greekman
- 10 Apr 2008 08:21
- 35 of 290
GlaxoSmithKline Plc, Europe's largest drugmaker, and Pfizer Inc. won a federal appeals court ruling shielding them from liability in lawsuits over the adequacy of warning labels on antidepressants approved by U.S. regulators.
For full info see http://www.bloomberg.com/apps/news?pid=20601100&sid=adakuLNpxXQo&refer=germany
Details about half way down page.
For full info see http://www.bloomberg.com/apps/news?pid=20601100&sid=adakuLNpxXQo&refer=germany
Details about half way down page.
greekman
- 21 May 2008 07:57
- 36 of 290
From RTT News.
RTT News said Tuesday that the U.S. Food and Drug Administration has approved their bowel drug Entereg to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.
http://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=611193%20&Category=Breaking%20News
RTT News said Tuesday that the U.S. Food and Drug Administration has approved their bowel drug Entereg to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.
http://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=611193%20&Category=Breaking%20News
greekman
- 22 May 2008 08:02
- 37 of 290
Bloomberg.
Europe's largest drugmaker (gsk) will sell more than 4 billion pounds of its top-selling Advair asthma inhaler, outgoing Chief Executive Officer Jean-Pierre Garnier told shareholders at the company's annual meeting.
Europe's largest drugmaker (gsk) will sell more than 4 billion pounds of its top-selling Advair asthma inhaler, outgoing Chief Executive Officer Jean-Pierre Garnier told shareholders at the company's annual meeting.
greekman
- 31 Jul 2008 18:06
- 38 of 290
Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need. At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary endpoint.
Should put the SP up a bit on opening.
Should put the SP up a bit on opening.
greekman
- 01 Aug 2008 08:09
- 39 of 290
Goes to show.
A real nice result re ofatumumab (multi billions) with figures twice what was required for minimum level acceptance, yet SP opens lower.
Yet another example of the global drag down of the markets bearing little reality (people will always need drugs) link to any individual company.
DOW well down, everything down.
A real nice result re ofatumumab (multi billions) with figures twice what was required for minimum level acceptance, yet SP opens lower.
Yet another example of the global drag down of the markets bearing little reality (people will always need drugs) link to any individual company.
DOW well down, everything down.
greekman
- 12 Aug 2008 08:10
- 40 of 290
Generic epilepsy drugs not interchangeable
by Michael Woodhead.
Patients with well-controlled epilepsy should not be switched to generic drugs because they may face loss of seizure control even with supposedly bio equivalent drugs, US neurologists say.
The Survey was sponsored by GSK so it does not have quite the sway of a completely independent one, but if it is excepted it could change the way that some generic drugs are looked at. Presumably similar surveys are conducted re other generic drugs effectiveness against none generic.
If not no doubt the big drug conglomerates will be jumping on the bandwagon, although as we all know with generic drugs being so much cheaper many can only afford such drugs.
Interesting all the same.
http://www.6minutes.com.au/articles/z1/view.asp?id=202221
by Michael Woodhead.
Patients with well-controlled epilepsy should not be switched to generic drugs because they may face loss of seizure control even with supposedly bio equivalent drugs, US neurologists say.
The Survey was sponsored by GSK so it does not have quite the sway of a completely independent one, but if it is excepted it could change the way that some generic drugs are looked at. Presumably similar surveys are conducted re other generic drugs effectiveness against none generic.
If not no doubt the big drug conglomerates will be jumping on the bandwagon, although as we all know with generic drugs being so much cheaper many can only afford such drugs.
Interesting all the same.
http://www.6minutes.com.au/articles/z1/view.asp?id=202221
greekman
- 13 Aug 2008 07:59
- 41 of 290
Whilst I know this settlement is old news it is interesting to see just how expensive such legal actions are.
The conclusion will leave other biotechs worrying whether, in the event of any dispute, license agreements with big pharma are worth the paper on which they are written. In the case of Biota, which found itself looking at a potential legal bill of A$100 million to see the case through to a trial, the answer is no.
See following for full article.
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=48435
The conclusion will leave other biotechs worrying whether, in the event of any dispute, license agreements with big pharma are worth the paper on which they are written. In the case of Biota, which found itself looking at a potential legal bill of A$100 million to see the case through to a trial, the answer is no.
See following for full article.
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=48435
Falcothou - 10 Oct 2008 09:52 - 42 of 290
Back at 10 support will it hold?
greekman
- 22 Oct 2008 15:22
- 43 of 290
Although not brilliant results to say the least, in todays climate any increase of EPS and dividend over what was expected is a bonus. It looks like GLAXO are being looked at as a defensive share again like it used to be in generally troubles financial times.
The main thing is there were NO shocks, so quietly happy with GSK.
The main thing is there were NO shocks, so quietly happy with GSK.
greekman
- 22 Oct 2008 17:27
- 44 of 290
At last 1 costly court case out of the way, with no doubt the only ones to realy gain are the lawyers.
Merix Pharmaceutical Corp. Settles False Advertising Litigation With GlaxoSmithKline.http://www.marketwatch.com/news/story/merix-pharmaceutical-corp-settles-false/story.aspx?guid=%7BD768B1F9-6C12-4206-A9BB-DF0970645BAB%7D&dist=hppr
Merix Pharmaceutical Corp. Settles False Advertising Litigation With GlaxoSmithKline.http://www.marketwatch.com/news/story/merix-pharmaceutical-corp-settles-false/story.aspx?guid=%7BD768B1F9-6C12-4206-A9BB-DF0970645BAB%7D&dist=hppr
greekman
- 10 Nov 2008 09:34
- 45 of 290
Hope they are right.
URCH Publishing: GlaxoSmithKline Will Overtake Pfizer to Become World's Largest Pharmaceutical Company by 2012.
Thought of sending for Pharmaceutical Market Trends, 2008 - 2012 but at 1350 decided a tad too expensive.
For full article http://www.pr-inside.com/urch-publishing-glaxosmithkline-will-r905661.htm
URCH Publishing: GlaxoSmithKline Will Overtake Pfizer to Become World's Largest Pharmaceutical Company by 2012.
Thought of sending for Pharmaceutical Market Trends, 2008 - 2012 but at 1350 decided a tad too expensive.
For full article http://www.pr-inside.com/urch-publishing-glaxosmithkline-will-r905661.htm
Falcothou - 21 Nov 2008 16:09 - 46 of 290
Approaching 10 again! Slightly tempted
Falcothou - 21 Nov 2008 16:19 - 47 of 290
Can't decide so won't
2:08GMT 21Nov2008-European pharmas suffers as risk appetite inches back
------------------------------------------------------------------------
Shares in European big cap pharma fall as investors see value in riskier
assets.
"What you are seeing now is that people may possibly move up the risk curve
a little bit in which case you see outflows out of the pharma sector," says an
analyst at a major bank. "Look at the chemicals sector that's reasonably strong
today."
"In relative terms pharma is not a cheap sector anymore if you look at one
year forward P/E relative or something like that. I think that is the sort of
macro trends we are looking at I don't think we are really seeing anything stock
specific.
Another analyst agrees, saying: "Maybe there's a bit of rotation, maybe
other sectors have become a bit too cheap relatively speaking".
He adds that with clients seeking to sell their stakes in funds, thin
volumes could suggest that clients may be asking fund managers are being forced
to selling off big cap holdings which often include pharmaceutical stocks.
At 12:32 GMT, Sanofi-Aventis was down 5.5 percent, Novartis was down 5.9
percent, Roche was down 5.4 percent, AstraZeneca was down 4.3 percent and
GlaxoSmithKline was down 3.1 percent.
2:08GMT 21Nov2008-European pharmas suffers as risk appetite inches back
------------------------------------------------------------------------
Shares in European big cap pharma fall as investors see value in riskier
assets.
"What you are seeing now is that people may possibly move up the risk curve
a little bit in which case you see outflows out of the pharma sector," says an
analyst at a major bank. "Look at the chemicals sector that's reasonably strong
today."
"In relative terms pharma is not a cheap sector anymore if you look at one
year forward P/E relative or something like that. I think that is the sort of
macro trends we are looking at I don't think we are really seeing anything stock
specific.
Another analyst agrees, saying: "Maybe there's a bit of rotation, maybe
other sectors have become a bit too cheap relatively speaking".
He adds that with clients seeking to sell their stakes in funds, thin
volumes could suggest that clients may be asking fund managers are being forced
to selling off big cap holdings which often include pharmaceutical stocks.
At 12:32 GMT, Sanofi-Aventis was down 5.5 percent, Novartis was down 5.9
percent, Roche was down 5.4 percent, AstraZeneca was down 4.3 percent and
GlaxoSmithKline was down 3.1 percent.
Falcothou - 21 Nov 2008 16:19 - 48 of 290
Can't decide so won't
2:08GMT 21Nov2008-European pharmas suffers as risk appetite inches back
------------------------------------------------------------------------
Shares in European big cap pharma fall as investors see value in riskier
assets.
"What you are seeing now is that people may possibly move up the risk curve
a little bit in which case you see outflows out of the pharma sector," says an
analyst at a major bank. "Look at the chemicals sector that's reasonably strong
today."
"In relative terms pharma is not a cheap sector anymore if you look at one
year forward P/E relative or something like that. I think that is the sort of
macro trends we are looking at I don't think we are really seeing anything stock
specific.
Another analyst agrees, saying: "Maybe there's a bit of rotation, maybe
other sectors have become a bit too cheap relatively speaking".
He adds that with clients seeking to sell their stakes in funds, thin
volumes could suggest that clients may be asking fund managers are being forced
to selling off big cap holdings which often include pharmaceutical stocks.
At 12:32 GMT, Sanofi-Aventis was down 5.5 percent, Novartis was down 5.9
percent, Roche was down 5.4 percent, AstraZeneca was down 4.3 percent and
GlaxoSmithKline was down 3.1 percent.
2:08GMT 21Nov2008-European pharmas suffers as risk appetite inches back
------------------------------------------------------------------------
Shares in European big cap pharma fall as investors see value in riskier
assets.
"What you are seeing now is that people may possibly move up the risk curve
a little bit in which case you see outflows out of the pharma sector," says an
analyst at a major bank. "Look at the chemicals sector that's reasonably strong
today."
"In relative terms pharma is not a cheap sector anymore if you look at one
year forward P/E relative or something like that. I think that is the sort of
macro trends we are looking at I don't think we are really seeing anything stock
specific.
Another analyst agrees, saying: "Maybe there's a bit of rotation, maybe
other sectors have become a bit too cheap relatively speaking".
He adds that with clients seeking to sell their stakes in funds, thin
volumes could suggest that clients may be asking fund managers are being forced
to selling off big cap holdings which often include pharmaceutical stocks.
At 12:32 GMT, Sanofi-Aventis was down 5.5 percent, Novartis was down 5.9
percent, Roche was down 5.4 percent, AstraZeneca was down 4.3 percent and
GlaxoSmithKline was down 3.1 percent.
greekman
- 19 Dec 2008 19:00
- 49 of 290
U.S. flu shows resistance to flu drug, CDC says.
A common strain of influenza circulating in the United States this winter is resistant to Tamiflu, the most popular drug used to treat it, federal health officials said on Friday. Tamiflu is made by Roche AG and Gilead Sciences Inc.
The USA don't use a lot of antiviral drugs. But Doctors have been advised to use either Relenza, or Zanamivir produced by Glaxo.
No doubt a similar finding would result in a UK testing project. If it does, I understand that as we do use more antiviral drugs (please correct me if I am wrong, as not a medical expert by any means) it would mean a far higher use of Zanamivir.
A common strain of influenza circulating in the United States this winter is resistant to Tamiflu, the most popular drug used to treat it, federal health officials said on Friday. Tamiflu is made by Roche AG and Gilead Sciences Inc.
The USA don't use a lot of antiviral drugs. But Doctors have been advised to use either Relenza, or Zanamivir produced by Glaxo.
No doubt a similar finding would result in a UK testing project. If it does, I understand that as we do use more antiviral drugs (please correct me if I am wrong, as not a medical expert by any means) it would mean a far higher use of Zanamivir.
Falcothou - 21 Jan 2009 08:23 - 50 of 290
Just can't quite crack 13 resistance, good Sterling hedge though with a divi
greekman
- 21 Jan 2009 10:27
- 51 of 290
Hi Falcothou,
Nice to see someone post. I was beginning to think there was only you and me left.
With interest rates forever falling and guilts having problems, and possibly heading for worse (how long before government bonds do not look as much a guilt edged bet as they are intended to be) I feel that when punters start looking at the Stock Markets again with less negativity, companies such as GSK will be the first to attract investment.
GSK being a strong global company, with as you say a decent divi that is paying more than most bank connected investments, will be in the forefront of any uplift..
Nice to see someone post. I was beginning to think there was only you and me left.
With interest rates forever falling and guilts having problems, and possibly heading for worse (how long before government bonds do not look as much a guilt edged bet as they are intended to be) I feel that when punters start looking at the Stock Markets again with less negativity, companies such as GSK will be the first to attract investment.
GSK being a strong global company, with as you say a decent divi that is paying more than most bank connected investments, will be in the forefront of any uplift..
Falcothou - 21 Jan 2009 13:19 - 52 of 290
Hi Greekman ,
Very tranquil here. I have partially hedged with an AZN short as they don't seem to have the product stream that GSK does. The more cable weakens the stronger the pharms seem to get. Rogers seems to be anticipating parity!As you say Sterling in the bank is taking on a Zimbawean shape wonder if we will reach parity with Zim dollar!
Very tranquil here. I have partially hedged with an AZN short as they don't seem to have the product stream that GSK does. The more cable weakens the stronger the pharms seem to get. Rogers seems to be anticipating parity!As you say Sterling in the bank is taking on a Zimbawean shape wonder if we will reach parity with Zim dollar!
greekman
- 21 Jan 2009 13:45
- 53 of 290
With Gordon Browns record of selling gold at its bottom price just prior to the price rocketing, I would not be surprised if he declared that as the started to tumble he had bought the Zim Dollar by the bucket load.
Cant really think of any strategy, financial or otherwise that has proved positive by this government. Just hope when/if they decide to pump money into the country via purchasing collateral in companies, institution, shares and the like, they don't consider GSK. Now that would be a kiss of death.
Rant over.
Cant really think of any strategy, financial or otherwise that has proved positive by this government. Just hope when/if they decide to pump money into the country via purchasing collateral in companies, institution, shares and the like, they don't consider GSK. Now that would be a kiss of death.
Rant over.
Falcothou - 24 Jan 2009 09:02 - 54 of 290
http://www.bloomberg.com/apps/news?pid=20601102&sid=ajZsqwPBrs20&refer=uk
greekman
- 27 Jan 2009 17:05
- 55 of 290
Could happen.
Stockbroker Collins Stewart is covering its bets and upgrading UK drugs company AstraZeneca to hold from sell on the off chance that it may become the subject of a bid with GlaxoSmithkline seen as the most feasible bidder.
Stockbroker Collins Stewart is covering its bets and upgrading UK drugs company AstraZeneca to hold from sell on the off chance that it may become the subject of a bid with GlaxoSmithkline seen as the most feasible bidder.
Falcothou - 27 Jan 2009 17:19 - 56 of 290
I hope not, that would really screw up my pairs trade! I would be happier if they hoovered up the cash strapped tiddlers with long patents and emerging market exposure which I gather from paper today is exactly what Pfizer didn't do.
greekman
- 27 Jan 2009 17:31
- 57 of 290
Glaxo have been delving into tiddler hoovering with drug patents of late. I feel Glaxo taking over Astra especially when they have already stated and implemented a more cash reserve strategy would be a long shot and possible an over reaching step too far, but as often said of late, normal market behaviour (if there ever was such a thing) went out of the window many months ago.
Falcothou - 27 Jan 2009 18:08 - 58 of 290
I would hope that GSK would take note of Fred the Shred and Rio's Behemoth ambititions,debt will not be in vogue for a while yet I hope, though these Bank bail-outs seem to be being used for bonuses and acquisitions (juicy m&a fees) rather than lending out to small fry.
kimoldfield
- 05 Feb 2009 12:47
- 59 of 290
A few points from the results today:-
Summary
EPS before major restructuring -9% CER, up 6% in sterling terms
-
excluding previously announced Q4 legal charge of 278 million, 2008 EPS 109.3p -6% CER as expected
-
net cash inflow from operating activities 7.3 billion up 19% in sterling terms
Early progress to globalise and diversify
-
Emerging Markets sales up 12% in 2008; 4 transactions executed
-
vaccines sales 2.5 billion up 15% aided by Cervarix and Rotarix
-
consumer brand acquisitions, including Biotene; EU approval of alli in January 2009
Sustained pipeline progress from discovery to approval:
-
12 products launched in 2008, including Promacta, Tyverb, Rotarix and Kinrix
-
17% of FDA approvals for NCEs and new vaccines in 2008
-
US filing of pazopanib and phase III start for Syncria announced today
-
more than 10 key products currently filed with regulators worldwide
-
30 assets in late-stage development
-
70 internal and external drug discovery engines
Existing restructuring programme expanded
-
pre-tax annual savings increased from 0.7 billion to 1.7 billion by 2011
-
pre-tax charges increased from 1.5 billion to 3.6 billion
-
savings in 2009 mitigate expected decline to gross margin due to product mix changes and support further investment behind strategic priorities
Cash flow
Net cash inflow from operating activities for the year was 7,311 million, up 19% in sterling terms. This was used to fund net interest paid of 410 million, capital expenditure on property, plant and equipment and intangible assets of 2,069 million, and acquisitions of 454 million. In addition, dividends paid to shareholders totalled 2,929 million (up 5% compared with 2007) and share repurchases amounted to 3,706 million. These, together with issuances of $9 billion under the US shelf registration statement and 700 million under the EMTN programme in the year, only partly offset by the repayment on maturity of existing debt, contributed to the increased cash position at 31st December 2008.
Net debt
Net debt increased by 4.1 billion during the year to 10.2 billion at 31st December 2008, comprising gross debt of 16.2 billion and cash and liquid investments of 6 billion.
The Group is well placed financially having completed its debt financing programme earlier in 2008. At 31st December 2008, GSK had short-term borrowings (including overdrafts) repayable within 12 months of only 1 billion with a further 0.7 billion repayable in the subsequent year.
Dividends
The Board has declared a fourth interim dividend of 17 pence per share resulting in a dividend for the year of 57 pence, a four pence increase over the dividend of 53 pence per share for 2007. The equivalent interim dividend receivable by ADR holders is 49.4564 cents per ADS based on an exchange rate of 1/$1.4546. The ex-dividend date will be 11th February 2009, with a record date of 13th February 2009 and a payment date of 9th April 2009.
Summary
EPS before major restructuring -9% CER, up 6% in sterling terms
-
excluding previously announced Q4 legal charge of 278 million, 2008 EPS 109.3p -6% CER as expected
-
net cash inflow from operating activities 7.3 billion up 19% in sterling terms
Early progress to globalise and diversify
-
Emerging Markets sales up 12% in 2008; 4 transactions executed
-
vaccines sales 2.5 billion up 15% aided by Cervarix and Rotarix
-
consumer brand acquisitions, including Biotene; EU approval of alli in January 2009
Sustained pipeline progress from discovery to approval:
-
12 products launched in 2008, including Promacta, Tyverb, Rotarix and Kinrix
-
17% of FDA approvals for NCEs and new vaccines in 2008
-
US filing of pazopanib and phase III start for Syncria announced today
-
more than 10 key products currently filed with regulators worldwide
-
30 assets in late-stage development
-
70 internal and external drug discovery engines
Existing restructuring programme expanded
-
pre-tax annual savings increased from 0.7 billion to 1.7 billion by 2011
-
pre-tax charges increased from 1.5 billion to 3.6 billion
-
savings in 2009 mitigate expected decline to gross margin due to product mix changes and support further investment behind strategic priorities
Cash flow
Net cash inflow from operating activities for the year was 7,311 million, up 19% in sterling terms. This was used to fund net interest paid of 410 million, capital expenditure on property, plant and equipment and intangible assets of 2,069 million, and acquisitions of 454 million. In addition, dividends paid to shareholders totalled 2,929 million (up 5% compared with 2007) and share repurchases amounted to 3,706 million. These, together with issuances of $9 billion under the US shelf registration statement and 700 million under the EMTN programme in the year, only partly offset by the repayment on maturity of existing debt, contributed to the increased cash position at 31st December 2008.
Net debt
Net debt increased by 4.1 billion during the year to 10.2 billion at 31st December 2008, comprising gross debt of 16.2 billion and cash and liquid investments of 6 billion.
The Group is well placed financially having completed its debt financing programme earlier in 2008. At 31st December 2008, GSK had short-term borrowings (including overdrafts) repayable within 12 months of only 1 billion with a further 0.7 billion repayable in the subsequent year.
Dividends
The Board has declared a fourth interim dividend of 17 pence per share resulting in a dividend for the year of 57 pence, a four pence increase over the dividend of 53 pence per share for 2007. The equivalent interim dividend receivable by ADR holders is 49.4564 cents per ADS based on an exchange rate of 1/$1.4546. The ex-dividend date will be 11th February 2009, with a record date of 13th February 2009 and a payment date of 9th April 2009.
Falcothou - 05 Feb 2009 13:01 - 60 of 290
Thanks Kim divi increase helpful with current savings rates
partridge
- 05 Feb 2009 13:14
- 61 of 290
And when you look at that cash generation (7.3Billion from operating activities), the divi looks safe for the time being.
greekman
- 05 Feb 2009 13:35
- 62 of 290
Agreed. It's as you say a good divi that looks safe. A lot more than can be said about general interests rates. Over the next 12 months I can see many investors coming back into the market looking for good divi returns, especially after the .5% drop in interest rates announced earlier today.
kimoldfield
- 05 Feb 2009 15:09
- 63 of 290
Lower sales, that was expected though. GSK has a bit of a debt but RBS can loose that much cash in 6 months, with nothing to show at the end!
Gary Pearson - 27 Feb 2009 11:19 - 64 of 290
Near 1 year low. Should this be in this market? As you said above good divi. Defensive which given that this bear isn't over yet should serve it well. Only slight concern will be the impact of falling dollar over the medium term on earnings.
Drugs pipeline?
Drugs pipeline?
Falcothou - 27 Feb 2009 12:05 - 65 of 290
http://sharecast.com/cgi-bin/sharecast/story.cgi?story_id=2632957
Gary Pearson - 27 Feb 2009 14:30 - 66 of 290
Thanks for that Falcothou. GDP seems to have polarised the market now and GSK defensive qualities are starting to shine through. Let's see if the consumer confidence figures later can help GSK's cause. I see S&P is predicted to open below key support at 741. Could be interesting. I think this could be the start of a nice run.
greekman
- 13 Mar 2009 08:04
- 67 of 290
Although there has been plenty of talk/rumour re Glaxo buying Astra recently, Glaxo have said that no such plans are in the offering.
But the news from the last few days, may just be a sign that a takeover will happen.
On a personal view....I have no idea, if such a deal would be good for Glaxo and the pharmaceutical sector or not.
The third huge pharmaceuticals deal of the year was struck yesterday as Roche agreed to buy the 44 per cent of Genentech that it did not already own for $46.8 billion (34 billion), giving the Swiss group scope to cut costs and complete control over a range of cancer drugs.
Merck have also agreed to buy Schering-Plough for $41.1 billion (29.8 billion) in a deal that would create the world's second-largest pharmaceuticals group.
But the news from the last few days, may just be a sign that a takeover will happen.
On a personal view....I have no idea, if such a deal would be good for Glaxo and the pharmaceutical sector or not.
The third huge pharmaceuticals deal of the year was struck yesterday as Roche agreed to buy the 44 per cent of Genentech that it did not already own for $46.8 billion (34 billion), giving the Swiss group scope to cut costs and complete control over a range of cancer drugs.
Merck have also agreed to buy Schering-Plough for $41.1 billion (29.8 billion) in a deal that would create the world's second-largest pharmaceuticals group.
Falcothou - 13 Mar 2009 08:10 - 68 of 290
Di-worsification imho,keep sucking in the minnows,too much indigestion with a big fish!
greekman
- 26 Mar 2009 09:59
- 69 of 290
Nice to be right sometimes. Why companies such as Glaxo are an even better bet.
A few months ago I mentioned that I expected investors to be looking a the Stock Markets again to make money, especially in the blue chip sector, mainly due to the low interest levels everywhere else.
I also mention that I thought the popular, so called 100% safe haven of Government Bonds would become a less safe investment due to the vast amounts being proposed by the government.
On reading todays Telegraph, I see that one of many proposed big auctions re these gilts has failed for the first time since 1995 to be fully taken up.
Fears are growing that the government may not be able to cover these gilts.
Obviously if an auction this early on in the list fails, then future auction prospects look poor.
Either the government will need to withdraw further bonds from auction (something they definitely can't do) or lower the price (something that will increase their direct debt).
You can't expect to flood the bond/guilt market and expect any other reaction that you would get from flooding any market. Surely that is basic economics.
They are quickly running out of get out clauses.
his makes the stock market taking in the risk/reward factor, although still of more risk than gilts, a much better bet.
All IMHO of course.
A few months ago I mentioned that I expected investors to be looking a the Stock Markets again to make money, especially in the blue chip sector, mainly due to the low interest levels everywhere else.
I also mention that I thought the popular, so called 100% safe haven of Government Bonds would become a less safe investment due to the vast amounts being proposed by the government.
On reading todays Telegraph, I see that one of many proposed big auctions re these gilts has failed for the first time since 1995 to be fully taken up.
Fears are growing that the government may not be able to cover these gilts.
Obviously if an auction this early on in the list fails, then future auction prospects look poor.
Either the government will need to withdraw further bonds from auction (something they definitely can't do) or lower the price (something that will increase their direct debt).
You can't expect to flood the bond/guilt market and expect any other reaction that you would get from flooding any market. Surely that is basic economics.
They are quickly running out of get out clauses.
his makes the stock market taking in the risk/reward factor, although still of more risk than gilts, a much better bet.
All IMHO of course.
greekman
- 20 Apr 2009 10:01
- 70 of 290
From the Press.
GlaxoSmithKline was in late stage talks on Sunday to acquire Stiefel Laboratories, a US maker of skin care pharmaceuticals, for roughly $3bn, according to a source close to the matter, says the FT.
Obviously such news is difficult to keep quiet, but as this was in the media over the week-end, but only officially released about 1 hour after UK market opened, (why not at 0700 as the Asian markets had already released it).
Of course no one privy to this info have acted prior to official release, Have they!
GlaxoSmithKline was in late stage talks on Sunday to acquire Stiefel Laboratories, a US maker of skin care pharmaceuticals, for roughly $3bn, according to a source close to the matter, says the FT.
Obviously such news is difficult to keep quiet, but as this was in the media over the week-end, but only officially released about 1 hour after UK market opened, (why not at 0700 as the Asian markets had already released it).
Of course no one privy to this info have acted prior to official release, Have they!
PCM - 20 Apr 2009 17:32 - 71 of 290
good article on GSK at www.tradinghelpdesk.com
Dil
- 21 Apr 2009 08:27
- 72 of 290
Are they paying you to ramp that site ?
greekman
- 01 May 2009 08:51
- 73 of 290
Many punters are suprised why the sp has not zoomed up due to Swine Flu and Relenza. Perhaps this is a reason.
10 Utahns, 2 others sue pharmaceutical company.
Not sure if this has anything to do with the sp over last few days not gaining as much as people expected, but it looks as if GSK have another law suit against hem. Perhaps it leaked out a few days ago.
http://www.deseretnews.com/article/1,5143,705300723,00.html
I appreciate all drug companies the size of Glaxo are always in a process of being sued by someone or other.
10 Utahns, 2 others sue pharmaceutical company.
Not sure if this has anything to do with the sp over last few days not gaining as much as people expected, but it looks as if GSK have another law suit against hem. Perhaps it leaked out a few days ago.
http://www.deseretnews.com/article/1,5143,705300723,00.html
I appreciate all drug companies the size of Glaxo are always in a process of being sued by someone or other.
greekman
- 05 May 2009 07:52
- 74 of 290
From Canna Zine News.
April 2009 will go down as the month the Glaxo SmithKline marketing department really earned their corn.
As a result of a nationwide campaign to sell GSK's new weight-loss drug Alli, (AKA Orlistat, AKA Xenical), it quickly became the fastest selling over-the-counter weight-loss medication..ever. And as if its success wasn't already assured, you can now find it in the pharmacy at your favourite branch of Tesco, Asda, Morrisons or Sainsbury's.
Ideal if you want to pick up some whilst shopping for burgers, buns and beer.
END.
The next 12/24 months is looking good for Glaxo's drug line. As they are loosing some drugs to generics, they need new lines such as Alli.
April 2009 will go down as the month the Glaxo SmithKline marketing department really earned their corn.
As a result of a nationwide campaign to sell GSK's new weight-loss drug Alli, (AKA Orlistat, AKA Xenical), it quickly became the fastest selling over-the-counter weight-loss medication..ever. And as if its success wasn't already assured, you can now find it in the pharmacy at your favourite branch of Tesco, Asda, Morrisons or Sainsbury's.
Ideal if you want to pick up some whilst shopping for burgers, buns and beer.
END.
The next 12/24 months is looking good for Glaxo's drug line. As they are loosing some drugs to generics, they need new lines such as Alli.
Falcothou - 05 May 2009 08:26 - 75 of 290
I know Big Pharma will probably never reach the dizzy heights it did in the distant past but as regulation and trials cost have increased and medicare budgets reduced life has become harder.For that reason generics seem to have an incredibly easy ride, no research cost just set up a high tech factory, bit of marketing and the dollars roll in. It would seem fairer if the patent should last longer to reflect this distortion
greekman
- 05 May 2009 09:57
- 76 of 290
Falcothou,
Fully Agree. The generic problem is hitting Glaxo and other big pharma's hard.
You only have to put Generic drugs into Google to see how big the business is getting. But a Google search also brings up many examples of Generic drugs having to be withdrawn. The figures do not make good reading (to the health of those taking generic drugs). Whilst I appreciate there is always a risk to ALL drugs of a side effect resulting in a withdrawal notice, you only have to look back at history (Thalidomide for example) to see the risks.
Saying that, generic drugs must be by testing standards far behind none generic in safety (unless someone out there can explain to a layman differently).
That google search re Generic drugs, makes scary reading.
I can see that in the not too distant future, such a drug will cause untold damage, then late as usual the powers that be will consider more the safety effect of a drug over cost. Cost appears to be a more important factor in the present climate.
The WHO already has powers that can be bought forward in a World Pandemic. One of these being that they can allow a generic drug to be produced, before the initial drug patent has expired.
Lessons it appears are soon forgot.
re the WHO powers re above. I read this somewhere over the week-end, but can't find it now. Anyone assist.
Fully Agree. The generic problem is hitting Glaxo and other big pharma's hard.
You only have to put Generic drugs into Google to see how big the business is getting. But a Google search also brings up many examples of Generic drugs having to be withdrawn. The figures do not make good reading (to the health of those taking generic drugs). Whilst I appreciate there is always a risk to ALL drugs of a side effect resulting in a withdrawal notice, you only have to look back at history (Thalidomide for example) to see the risks.
Saying that, generic drugs must be by testing standards far behind none generic in safety (unless someone out there can explain to a layman differently).
That google search re Generic drugs, makes scary reading.
I can see that in the not too distant future, such a drug will cause untold damage, then late as usual the powers that be will consider more the safety effect of a drug over cost. Cost appears to be a more important factor in the present climate.
The WHO already has powers that can be bought forward in a World Pandemic. One of these being that they can allow a generic drug to be produced, before the initial drug patent has expired.
Lessons it appears are soon forgot.
re the WHO powers re above. I read this somewhere over the week-end, but can't find it now. Anyone assist.
greekman
- 05 May 2009 16:28
- 77 of 290
News just out (But not yet on MoneyAm).
News just out re increase in prescriptions of antiviral (USA).The number of U.S. antiviral retail prescriptions soared to 277,196 for the week that ended May 1, compared with 14,366 for the week that ended April 24, according to pharmaceutical market research company SDI. (Massive increase)
These show, that more than 90 percent of the antiviral prescriptions were dispensed for Tamiflu. About 5 percent were written for GlaxoSmithKline Plc's Relenza, with the rest for older drugs.
This is no doubt one of the reasons for Glaxo poor sp of last few days. Although just released it has been in the media for several days, that Tamiflu sales are far out pacing Relenza.
As per the next few weeks/months...Due to the continuing increase in statements that Tamiflu is having less effect (resistance), no doubt the percentage of sales will have a turnaround effect. According to many articles, the general feeling is that Relenza will take over the lead in sales.
Note... As a test I have contacted 2 drug supply companies. Both have sold out of Relenza with both offering Tamiflu as an alternative. Try it yourself. Shows that Glaxo need to up production asap, which according to another article they are in the process of doing.
News just out re increase in prescriptions of antiviral (USA).The number of U.S. antiviral retail prescriptions soared to 277,196 for the week that ended May 1, compared with 14,366 for the week that ended April 24, according to pharmaceutical market research company SDI. (Massive increase)
These show, that more than 90 percent of the antiviral prescriptions were dispensed for Tamiflu. About 5 percent were written for GlaxoSmithKline Plc's Relenza, with the rest for older drugs.
This is no doubt one of the reasons for Glaxo poor sp of last few days. Although just released it has been in the media for several days, that Tamiflu sales are far out pacing Relenza.
As per the next few weeks/months...Due to the continuing increase in statements that Tamiflu is having less effect (resistance), no doubt the percentage of sales will have a turnaround effect. According to many articles, the general feeling is that Relenza will take over the lead in sales.
Note... As a test I have contacted 2 drug supply companies. Both have sold out of Relenza with both offering Tamiflu as an alternative. Try it yourself. Shows that Glaxo need to up production asap, which according to another article they are in the process of doing.
Falcothou - 05 May 2009 16:46 - 78 of 290
Glaxo is only low because it is a defensive and who wants a 8% yield when at the moment but for not much longer, you can make it on a bank share in a morning. Tamiflu does have some nasty side effects e.g. 18 suicides in Japanese adolescents. nausea, vomiting confusion. Pharma are also under attack from counterfeit drugs(organised crime) and they are not going to counterfeit generics because the profit aren't there. I think the government has got it wrong...if this is a mild strain of swine flu people should be queueing up to get infected by it to generate antibodies rather than hiding away, those affected in first batch in 1918 tended to survive the more vicious second strain....
greekman
- 05 May 2009 17:33
- 79 of 290
The divi is very solid though. That is one of the reasons I increased my holdings last Friday (not the best timed buy).
I would be looking at banks more if I was not now fully committed to long plays.
I do agree re the comment...should be queueing up to get infected by it to generate antibodies rather than hiding away, those affected in first batch in 1918 tended to survive the more vicious second strain....
I hate to say anything in our governments favour, but the problem all Governments have is dammed if you do dammed if you don't.
If this strain had developed into a more serious strain and the world governments had not 'pressed the button' there would have been hell to play. I feel that for the same reason (they dare not get it wrong) so they can not say anything else but to stay clear of infected people.
But when/if this does come back toward winter (the flu season) with a vengeance, those who have been exposed will no doubt be the best armed to fight it.
I would be looking at banks more if I was not now fully committed to long plays.
I do agree re the comment...should be queueing up to get infected by it to generate antibodies rather than hiding away, those affected in first batch in 1918 tended to survive the more vicious second strain....
I hate to say anything in our governments favour, but the problem all Governments have is dammed if you do dammed if you don't.
If this strain had developed into a more serious strain and the world governments had not 'pressed the button' there would have been hell to play. I feel that for the same reason (they dare not get it wrong) so they can not say anything else but to stay clear of infected people.
But when/if this does come back toward winter (the flu season) with a vengeance, those who have been exposed will no doubt be the best armed to fight it.
greekman
- 06 May 2009 11:02
- 80 of 290
Latest re Wellbutrin XL,
Looking at the figures, the sale of Wellbutrin XL looks to be very much in Glaxo's favour. Or am I missing something.
Looking at the figures, the sale of Wellbutrin XL looks to be very much in Glaxo's favour. Or am I missing something.
Clubman3509
- 06 May 2009 11:07
- 81 of 290
I think 900 would be a good buying oppertunity, as IMHO Swine Flu will return big style this winter with many deaths worldwide.
partridge
- 06 May 2009 12:41
- 82 of 290
Recent first quarter results not great, owing primarily to generic competition in the USA, but cash generated from operations still $1.7billion in three months and small increase in dividend helps confidence. I have held for very many years and GSK remains a core long term holding in my PEP/ISA.
jkd - 06 May 2009 22:35 - 83 of 290
p
i have every respect for all your posts.
i do hope you wont mind me suggesting that some growth stocks grow, sort of, well i mean grow old. cant see us getting 2for1 on a regular basis anymore for the long term,
sometimes we need to look for the next Glaxo.
regards
jkd
i have every respect for all your posts.
i do hope you wont mind me suggesting that some growth stocks grow, sort of, well i mean grow old. cant see us getting 2for1 on a regular basis anymore for the long term,
sometimes we need to look for the next Glaxo.
regards
jkd
greekman
- 07 May 2009 07:56
- 84 of 290
Morning Jkd,
Could be right, who knows, but I sold out of Reckitt Benckiser 2 years ago thinking the same. Big mistake.
I am looking at Glaxo as the most solid share in my portfolio.
Could be right, who knows, but I sold out of Reckitt Benckiser 2 years ago thinking the same. Big mistake.
I am looking at Glaxo as the most solid share in my portfolio.
partridge
- 07 May 2009 09:16
- 85 of 290
Hi jkd
Agree with greek that you may be right (Jim Slaters "elephants don't gallop"etc) but long term return on my GSK is astounding and whilst they may now be in the "cash cow" stage of their business life they do not yet appear to be heading for decline. I learnt long ago that if you invest in companies with lots of potential, but not yet profitable or cash generative, you need a good spread for the occasional "star" to hopefully make up for all those which will lose you money. Personally I have found it more lucrative to stick to decent proven businesses and try to buy quality at or near the right time ("buy on the bad news, sell on the good" maxim has a lot going for it imo)
Agree with greek that you may be right (Jim Slaters "elephants don't gallop"etc) but long term return on my GSK is astounding and whilst they may now be in the "cash cow" stage of their business life they do not yet appear to be heading for decline. I learnt long ago that if you invest in companies with lots of potential, but not yet profitable or cash generative, you need a good spread for the occasional "star" to hopefully make up for all those which will lose you money. Personally I have found it more lucrative to stick to decent proven businesses and try to buy quality at or near the right time ("buy on the bad news, sell on the good" maxim has a lot going for it imo)
greekman
- 07 May 2009 10:02
- 86 of 290
Are the FDA none bias.
A 'very' long article so for those interested see http://www.aei.org/outlook/26859
Avandia (Glaxo) is mentioned about 2 para down. Makes you wonder.
A 'very' long article so for those interested see http://www.aei.org/outlook/26859
Avandia (Glaxo) is mentioned about 2 para down. Makes you wonder.
greekman
- 08 May 2009 07:36
- 87 of 290
Sanofi-Aventis SA of Paris, Baxter International Inc. of Deerfield, Illinois, and GlaxoSmithKline Plc of London are talking with world health authorities about producing shots, the agency said.
Fairly long article, but worth a read.
http://www.bloomberg.com/apps/news?pid=20601110&sid=aUgFPjCFldbw
Fairly long article, but worth a read.
http://www.bloomberg.com/apps/news?pid=20601110&sid=aUgFPjCFldbw
greekman
- 12 May 2009 08:27
- 88 of 290
RNS....GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company.
Another string added to Glaxo's strategic collaboration plan.
Another string added to Glaxo's strategic collaboration plan.
Falcothou - 12 May 2009 19:53 - 89 of 290
Cherry picking, grasping the low hanging fruit
greekman
- 13 May 2009 07:57
- 90 of 290
Morning Falcothou,
A bit of a mixed metaphor.
Cherry picking.....Taking the pick of the Litter or fruit.
Low hanging fruit.... Is never as sweet or as ripe as the fruit at the top of the tree.
I often mix my metaphors, as it makes life more interesting.
Not having a dig, just thought it humorous (made me smile).
Regards Greek.
A bit of a mixed metaphor.
Cherry picking.....Taking the pick of the Litter or fruit.
Low hanging fruit.... Is never as sweet or as ripe as the fruit at the top of the tree.
I often mix my metaphors, as it makes life more interesting.
Not having a dig, just thought it humorous (made me smile).
Regards Greek.
Falcothou - 13 May 2009 09:07 - 91 of 290
May be they are doing a combination, I have now idea about the fundies of the companies they are hoovering up, though pharma seems generally as a sector to be out of favour, so I would hope that they are at some discount. Apologise for the mixed metaphors I confused myself
greekman
- 13 May 2009 11:55
- 92 of 290
No prob, as said it made me smile, and as you say they may be doing a bit of both.
Sorry if off thread but another mixed metaphor. 'Honourable Member of Parliament'.
Sorry if off thread but another mixed metaphor. 'Honourable Member of Parliament'.
greekman
- 11 Jun 2009 17:33
- 93 of 290
As the WHO have now declared a Pandemic, there is a list of countries that are putting or already have a declared Pandemic plan into operation.
http://news.bbc.co.uk/1/hi/world/americas/8022516.stm
As with most bad situations, it will be a case of money being made by the barrow load. Its an ill wind, etc.
Just one quoted example......The US has a stockpile of 50 million courses of anti-viral drugs and has begun distributing the medication. It will spend $251m to buy 13 million more courses of flu medicine. Multiply this several times and it will show just how many millions of doses will be required, world wide.
Whilst under such measures, drugs under patent can be manufactured by none patent holding companies, no doubt a licence fee is still required to be paid to the patent holding company.
Surprised this has not had more effect on the sp.
http://news.bbc.co.uk/1/hi/world/americas/8022516.stm
As with most bad situations, it will be a case of money being made by the barrow load. Its an ill wind, etc.
Just one quoted example......The US has a stockpile of 50 million courses of anti-viral drugs and has begun distributing the medication. It will spend $251m to buy 13 million more courses of flu medicine. Multiply this several times and it will show just how many millions of doses will be required, world wide.
Whilst under such measures, drugs under patent can be manufactured by none patent holding companies, no doubt a licence fee is still required to be paid to the patent holding company.
Surprised this has not had more effect on the sp.
Falcothou - 11 Jun 2009 22:34 - 94 of 290
http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=2828597
SP is rudderless Greek , cable not helping, or California being broke
SP is rudderless Greek , cable not helping, or California being broke
greekman
- 12 Jun 2009 07:40
- 95 of 290
Morning Falcothou,
Broke or not, if the money needed to fight this pandemic is not forthcoming, the cost to these countries will be phenomenal. The world can not afford to not spend the required money. An untreated pandemic will cost far more to the world economy.
As to the sp, I can only agree with you. It matters not what we feel the true sp value is, if the market feels differently.
By the way, it would be nice to see someone else posting. It appears there is only a few of us left on MoneyAm interested in GSK.
Regards Greek.
Broke or not, if the money needed to fight this pandemic is not forthcoming, the cost to these countries will be phenomenal. The world can not afford to not spend the required money. An untreated pandemic will cost far more to the world economy.
As to the sp, I can only agree with you. It matters not what we feel the true sp value is, if the market feels differently.
By the way, it would be nice to see someone else posting. It appears there is only a few of us left on MoneyAm interested in GSK.
Regards Greek.
Falcothou - 12 Jun 2009 07:48 - 96 of 290
I've got a hunch we're not the only shareholders
greekman
- 12 Jun 2009 08:09
- 97 of 290
Interesting point re cost/affordability.
LONDON, June 12 (Reuters) - British pharmaceutical firm GlaxoSmithKline is planning to cut the prices of many of its leading medicines in emerging markets, CEO Andrew Witty said in an interview with the Financial Times.
"Making sure the price-volume equation is right is a key piece of the strategy," Witty was quoted as saying in the paper's Friday edition.
The plan follows the success of a pilot programme in the Philippines, the paper said. Speaking from the Philippines, Witty said a 60 percent cut in the local price of its cervical cancer vaccine Cervarix had increased sales eightfold.
Presume the cost of Relenza to the customer will reduce as volume increases.
LONDON, June 12 (Reuters) - British pharmaceutical firm GlaxoSmithKline is planning to cut the prices of many of its leading medicines in emerging markets, CEO Andrew Witty said in an interview with the Financial Times.
"Making sure the price-volume equation is right is a key piece of the strategy," Witty was quoted as saying in the paper's Friday edition.
The plan follows the success of a pilot programme in the Philippines, the paper said. Speaking from the Philippines, Witty said a 60 percent cut in the local price of its cervical cancer vaccine Cervarix had increased sales eightfold.
Presume the cost of Relenza to the customer will reduce as volume increases.
Falcothou - 12 Jun 2009 08:37 - 98 of 290
Break out above 1080?
XSTEFFX
- 13 Jun 2009 14:03
- 99 of 290
Please I hope your right.
greekman
- 30 Jun 2009 09:19
- 100 of 290
Just a thought.
Could the almost none upward movement of companies such as Glaxo be down to fear.
Whilst there is always the chance of a drug scare release knocking Glaxo's profits, could it be that many punters, PI's as well as institutional investors are in the present financial climate putting more downside on the risk than in so called normal times. In other words are such drug companies as defensive as other so called defensive stock.
There will as we know always be the risk of a adverse report knocking the sp. An example as such follows (could this have been one reason for yesterdays dip)
Tylenol ban will hurt the bottom line.
On Monday, a consortium of drug companies lobbied to an FDA panel, saying, products that include acetaminophen (Tylenol) should stay on the market despite concerns of widespread liver damage. Drug manufacturers offered to more clearly warn buyers about the risks of liver damage linked to the Tylenol instead of the FDAs more drastic options: a full-out ban.
http://seekingalpha.com/instablog/435872-www-threebrothershealth-com/10611-tylenol-ban-will-hurt-the-bottom-line
Investors tend to look at the negative sections of such reports....'An FDA ban, or a strict warning, will hurt the bottom-line of these companies'......
instead of looking to the positive effect if these companies win their augment.
Until investors start looking at risk in prospective and excepting that shares in any company no matter how safe they are perceived to be are still a risk, drug companies especially the majors will stagnate at least until confidence in the general financial situation improvises. It is only then that negative reports will be looked at as part of the territory, and these companies will get back to being in their truly defensive positions.
All obviously IMHO.
Could the almost none upward movement of companies such as Glaxo be down to fear.
Whilst there is always the chance of a drug scare release knocking Glaxo's profits, could it be that many punters, PI's as well as institutional investors are in the present financial climate putting more downside on the risk than in so called normal times. In other words are such drug companies as defensive as other so called defensive stock.
There will as we know always be the risk of a adverse report knocking the sp. An example as such follows (could this have been one reason for yesterdays dip)
Tylenol ban will hurt the bottom line.
On Monday, a consortium of drug companies lobbied to an FDA panel, saying, products that include acetaminophen (Tylenol) should stay on the market despite concerns of widespread liver damage. Drug manufacturers offered to more clearly warn buyers about the risks of liver damage linked to the Tylenol instead of the FDAs more drastic options: a full-out ban.
http://seekingalpha.com/instablog/435872-www-threebrothershealth-com/10611-tylenol-ban-will-hurt-the-bottom-line
Investors tend to look at the negative sections of such reports....'An FDA ban, or a strict warning, will hurt the bottom-line of these companies'......
instead of looking to the positive effect if these companies win their augment.
Until investors start looking at risk in prospective and excepting that shares in any company no matter how safe they are perceived to be are still a risk, drug companies especially the majors will stagnate at least until confidence in the general financial situation improvises. It is only then that negative reports will be looked at as part of the territory, and these companies will get back to being in their truly defensive positions.
All obviously IMHO.
greekman
- 03 Jul 2009 08:41
- 101 of 290
TOKYO (Reuters) - Japan has confirmed its first case of a genetic mutation of the new H1N1 flu virus that shows resistance to Tamiflu, the main antiviral flu drug, a health ministry official said on Thursday.
The patient was given Relenza and recovered, and does not appear to have infected anyone else.
Could this be the first move toward Relenza taking over.
And what will happen if the H1N1 virus mutates to a higher level that Relenza can't touch. A bit scary coupled with the figures of late that up to 100,000 persons in the UK per day could catch the virus. Good job it is not a more virulent strain. Of course we can trust our government 100% to be prepared for such an eventuality, Yer right.
http://www.reuters.com/article/internal_ReutersNewsRoom_ExclusivesAndWins_MOLT/idUSTRE5614TW20090702
The patient was given Relenza and recovered, and does not appear to have infected anyone else.
Could this be the first move toward Relenza taking over.
And what will happen if the H1N1 virus mutates to a higher level that Relenza can't touch. A bit scary coupled with the figures of late that up to 100,000 persons in the UK per day could catch the virus. Good job it is not a more virulent strain. Of course we can trust our government 100% to be prepared for such an eventuality, Yer right.
http://www.reuters.com/article/internal_ReutersNewsRoom_ExclusivesAndWins_MOLT/idUSTRE5614TW20090702
greekman
- 06 Jul 2009 08:30
- 102 of 290
Saturday July 04 2009
EVERYONE in Ireland is shortly to be offered a free swine flu vaccination as health authorities brace themselves for a worst-case scenario of up to 100,000 new cases a week.
Glaxo is mentioned in full article.
No doubt Scotland will get the same before the poor neighbour (England) get it.
http://www.independent.ie/national-news/swine-flu-jab-for-all-after-virus-toll-alert-1805686.html
EVERYONE in Ireland is shortly to be offered a free swine flu vaccination as health authorities brace themselves for a worst-case scenario of up to 100,000 new cases a week.
Glaxo is mentioned in full article.
No doubt Scotland will get the same before the poor neighbour (England) get it.
http://www.independent.ie/national-news/swine-flu-jab-for-all-after-virus-toll-alert-1805686.html
greekman
- 10 Jul 2009 08:05
- 103 of 290
WASHINGTON, July 9 (Reuters) - The U.S. government will pay for any vaccination program against the H1N1 swine flu, and may encourage schools to help vaccinate children, Health and Human Services Secretary Kathleen Sebelius said on Thursday. The government is also considering buying even more antiviral drugs, including more of GlaxoSmithKline's inhaled drug Relenza and pediatric doses of Roche AG's Tamiflu, officials told a swine flu "summit" at the National Institutes of Health.
Falcothou - 10 Jul 2009 08:12 - 104 of 290
Dd you get your divi yesterday Greek? It all helps...
greekman
- 10 Jul 2009 09:02
- 105 of 290
Morning Falcothou,
Yes, and a you say it does help. Glaxo's divi must be one of the best in the market. Appreciate it is not the highest but it is high and looks very safe.
I hope other countries follow the lead of the USA re their decision re Relenza. I would have expected the sp to be a bit higher on opening, but I suppose the increased revenue from Relenza is just a spit in the ocean for GSK.
I have never forecast an SP before regarding a future forecast but I took the bait a few months ago and forecast 15 by end of March 2010. I still feel that with Galxo's new direction re more add ons or/and joint ventures coupled with their expansion into the health food/drink field this is still achievable.
Obviously only a personal view.
Nice to have a bit of company on here.
Yes, and a you say it does help. Glaxo's divi must be one of the best in the market. Appreciate it is not the highest but it is high and looks very safe.
I hope other countries follow the lead of the USA re their decision re Relenza. I would have expected the sp to be a bit higher on opening, but I suppose the increased revenue from Relenza is just a spit in the ocean for GSK.
I have never forecast an SP before regarding a future forecast but I took the bait a few months ago and forecast 15 by end of March 2010. I still feel that with Galxo's new direction re more add ons or/and joint ventures coupled with their expansion into the health food/drink field this is still achievable.
Obviously only a personal view.
Nice to have a bit of company on here.
greekman
- 12 Jul 2009 12:10
- 106 of 290
From The Sunday Times July 12, 2009
Everyone will get vaccine against swine flu.
Jon Ungoed-Thomas
The NHS is preparing to vaccinate the entire population against swine flu after the disease claimed the life of its first healthy British patient.
A new vaccine is expected to arrive in Britain in the next few weeks and could be fast-tracked through regulatory approval in five days.
As many as 20m people could be inoculated this year. Ministers have secured up to 90m doses, and the rest of the population is likely to be offered vaccinations next year.
The first patients in the queue for the jab - being supplied to the UK by GSK and Baxter Healthcare -
Full article.....
http://www.timesonline.co.uk/tol/news/uk/health/article6689955.ece
Whilst no one wishes this Flu to spread or mutate, it undoubtedly will do both, and as with all disasters, natural or otherwise there are many companies and/or individuals that will make vast amounts of money.
Everyone will get vaccine against swine flu.
Jon Ungoed-Thomas
The NHS is preparing to vaccinate the entire population against swine flu after the disease claimed the life of its first healthy British patient.
A new vaccine is expected to arrive in Britain in the next few weeks and could be fast-tracked through regulatory approval in five days.
As many as 20m people could be inoculated this year. Ministers have secured up to 90m doses, and the rest of the population is likely to be offered vaccinations next year.
The first patients in the queue for the jab - being supplied to the UK by GSK and Baxter Healthcare -
Full article.....
http://www.timesonline.co.uk/tol/news/uk/health/article6689955.ece
Whilst no one wishes this Flu to spread or mutate, it undoubtedly will do both, and as with all disasters, natural or otherwise there are many companies and/or individuals that will make vast amounts of money.
Falcothou - 13 Jul 2009 07:48 - 107 of 290
As I understand a virus survives by mutating especially when it comes up against disease resistance.
Very interesting website and book Greek if you are interested in nutrition and how the body adapts to mineral/ vitamin defiencies
http://www.mybodylanguage.co.uk/
Very interesting website and book Greek if you are interested in nutrition and how the body adapts to mineral/ vitamin defiencies
http://www.mybodylanguage.co.uk/
greekman
- 13 Jul 2009 07:57
- 108 of 290
According to todays Yorkshire Post, the British Government have signed a contract with manufacturers GSK and Baxter to supply up to 132 million doses of swine flu vaccine.
May have been published earlier, but I have not seen the figures before.
Falcothou,
Just looked through the website www.mybodylanguage.co.uk, looks interesting.
Plain speaking and easy to understand.
May have been published earlier, but I have not seen the figures before.
Falcothou,
Just looked through the website www.mybodylanguage.co.uk, looks interesting.
Plain speaking and easy to understand.
Falcothou - 13 Jul 2009 08:28 - 109 of 290
That's a lot of doses, I wasn't sure who was doing supplying, good for Glaxo
It's written by a forensic scientist, his wife got huge cravings for lettuce(6/day) because of it's anti-carciogenic properties... it transpired she had breast cancer!The book is quite funny e.g. sex with the milkman... regarding a woman who has a milk allergy and she reacts badly to her husband' semen if he drinks milk!
It's written by a forensic scientist, his wife got huge cravings for lettuce(6/day) because of it's anti-carciogenic properties... it transpired she had breast cancer!The book is quite funny e.g. sex with the milkman... regarding a woman who has a milk allergy and she reacts badly to her husband' semen if he drinks milk!
greekman
- 18 Jul 2009 17:14
- 110 of 290
I have been puzzled why if the cost of a single coarse of Relenza is far cheaper than a single coarse of Tamiflu as to why Tamiflu appears to be the drug of choice. Also according to an article in the Lancett, Tamiflu has more side effects than Relenza. The following article goes some way to an explanation although with cost tending to be the main driving factor behind most drugs prescribed or/and recommended by Governments, I do feel I am still missing something.
I appreciate the article is a couple of months old.
Is Tamiflu 'better' than Relenza?
Posted in BCP Confidential by Nathaniel Forbes on 2009/05/12 17:04:46
I can find no clinical evidence that Roche's Tamiflu is more effective than GlaxoSmithKline's less-prescribed Relenza against Type A influenza like H1N1 and H5N1.
Japanese health inspector in goggles, mask, gloves and gown interviews passengers on a flight arriving in Tokyo from the U.S. on May 2, 2009
I have found abundant evidence, however, that Switzerland-based Roche has run marketing circles around U.K.-based GlaxoSmithKline (GSK) by emphasizing the convenience of swallowing a Tamiflu capsule over the hassle of inhaling Relenza powder.
That's the only reason I can imagine why a dose of Tamiflu is two to three times as expensive as a dose of Relenza. A dose of 75mg Tamiflu costs US$5 to US$10 at Internet pharmacies, but a dose of 5mg Relenza costs only US$2.50 to US$3.50. Both require prescriptions.
See link for full article
http://www.zdnetasia.com/blogs/bcp/0,3800011228,63010743,00.htm
I appreciate the article is a couple of months old.
Is Tamiflu 'better' than Relenza?
Posted in BCP Confidential by Nathaniel Forbes on 2009/05/12 17:04:46
I can find no clinical evidence that Roche's Tamiflu is more effective than GlaxoSmithKline's less-prescribed Relenza against Type A influenza like H1N1 and H5N1.
Japanese health inspector in goggles, mask, gloves and gown interviews passengers on a flight arriving in Tokyo from the U.S. on May 2, 2009
I have found abundant evidence, however, that Switzerland-based Roche has run marketing circles around U.K.-based GlaxoSmithKline (GSK) by emphasizing the convenience of swallowing a Tamiflu capsule over the hassle of inhaling Relenza powder.
That's the only reason I can imagine why a dose of Tamiflu is two to three times as expensive as a dose of Relenza. A dose of 75mg Tamiflu costs US$5 to US$10 at Internet pharmacies, but a dose of 5mg Relenza costs only US$2.50 to US$3.50. Both require prescriptions.
See link for full article
http://www.zdnetasia.com/blogs/bcp/0,3800011228,63010743,00.htm
Falcothou - 18 Jul 2009 18:23 - 111 of 290
Second quarter results from the drug giant GlaxoSmithKline are due Wednesday. Charles Stanley is looking for a 14% increase in year on year sales to 6.7bn. By contrast, operating margins are likely to be adversely impacted by the significant off-patent pressure over 2008 caused by the loss of Lamictal, Imitrex, Wellbutrin XL and Paxil CR as well as the ongoing pressure on former blockbuster diabetes product Avandia, the broker says.
Aside from the figures, analysts will be keen to see if the firm has anything to say about the H1N1 Virus outbreak. In a recent note on the company, Panmure Gordon said: GSK should benefit from the situation medium term, and it is worth noting that GSK received an order from the US government totalling US$71m for its adjuvant technology, which should provide upside to forecasts beyond any specific H1N1 vaccine the company manufactures.
Aside from the figures, analysts will be keen to see if the firm has anything to say about the H1N1 Virus outbreak. In a recent note on the company, Panmure Gordon said: GSK should benefit from the situation medium term, and it is worth noting that GSK received an order from the US government totalling US$71m for its adjuvant technology, which should provide upside to forecasts beyond any specific H1N1 vaccine the company manufactures.
Falcothou - 18 Jul 2009 18:25 - 112 of 290
Greek I'm confused as to why Astra has been out-performing Glax when it has no swine flu drugs and supposedly a more limited pipeline. Looking for a Astra shorting opportunity for hedging
kimoldfield
- 19 Jul 2009 16:24
- 113 of 290
Glaxosmithkline is in line to receive a 1.3bn sales injection from the global swine flu pandemic as concerns about the virus rise.
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/5858430/GSK-in-line-for-1.3bn-swine-flu-booster.html
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/5858430/GSK-in-line-for-1.3bn-swine-flu-booster.html
greekman
- 19 Jul 2009 17:20
- 114 of 290
Falcothou,
My only thought is that due to Glaxo's sp going nowhere over the last few years, it has effected how punters look at the company, IE confidence is lacking on the SP's reliability to hold it's value.
I feel that due to their future prospects with the new direction and dividend they are a good couple of below value.
Kimoldfield,
Read the Telegraph article, and it does look very promising, especially the mention of probable Relenza sales as well as the prospects for their vaccine.
Greek.
My only thought is that due to Glaxo's sp going nowhere over the last few years, it has effected how punters look at the company, IE confidence is lacking on the SP's reliability to hold it's value.
I feel that due to their future prospects with the new direction and dividend they are a good couple of below value.
Kimoldfield,
Read the Telegraph article, and it does look very promising, especially the mention of probable Relenza sales as well as the prospects for their vaccine.
Greek.
skinny
- 22 Jul 2009 12:34
- 115 of 290
Oh well - at least its a step in the right direction!
skinny
- 22 Jul 2009 14:26
- 116 of 290
GlaxoSmithKline Expects Further Swine Flue Vaccine Orders
LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) Wednesday said it will start shipping a new vaccine for H1N1 pandemic flu, dubbed swine flu, by September, and expects further significant orders.
GlaxoSmithKline said Wednesday it has orders for 195 million doses of the vaccine from governments, and is in talks with another 50.
Chief Executive Andrew Witty told reporters Wednesday the drug maker believes it will be able to make enough of the vaccine, and its existing antiviral Relenza, to satisfy current levels of demand.
"I expect further significant orders," said Witty.
Company Web site: www.gsk.com
LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) Wednesday said it will start shipping a new vaccine for H1N1 pandemic flu, dubbed swine flu, by September, and expects further significant orders.
GlaxoSmithKline said Wednesday it has orders for 195 million doses of the vaccine from governments, and is in talks with another 50.
Chief Executive Andrew Witty told reporters Wednesday the drug maker believes it will be able to make enough of the vaccine, and its existing antiviral Relenza, to satisfy current levels of demand.
"I expect further significant orders," said Witty.
Company Web site: www.gsk.com
greekman
- 24 Jul 2009 11:01
- 117 of 290
But will the vaccine produced by GSK work as the H1N1 virus must be mutating!
For months now the graphics of the bug, shown on our TV screens have always been blue, but for a few days now they consistently change to red.
Presumably the WHO have noticed, although I could never understand what a 1964
pop group has to do with Swine flu.
Now who said, Tamiflu doesn't have side effects. Next time I will try Relenza.
For months now the graphics of the bug, shown on our TV screens have always been blue, but for a few days now they consistently change to red.
Presumably the WHO have noticed, although I could never understand what a 1964
pop group has to do with Swine flu.
Now who said, Tamiflu doesn't have side effects. Next time I will try Relenza.
Falcothou - 26 Jul 2009 22:30 - 118 of 290
I wonder which of these Sarkozy is on re. fainting. I favour the latter
Medications that can cause low blood pressure
Some medications you may take can also cause low blood pressure, including:
Diuretics (water pills)
Alpha blockers
Beta blockers
Drugs for Parkinson's disease
Certain types of antidepressants (tricyclic antidepressants)
Sildenafil (Viagra), particularly in combination with another heart medication, nitroglycerine
Medications that can cause low blood pressure
Some medications you may take can also cause low blood pressure, including:
Diuretics (water pills)
Alpha blockers
Beta blockers
Drugs for Parkinson's disease
Certain types of antidepressants (tricyclic antidepressants)
Sildenafil (Viagra), particularly in combination with another heart medication, nitroglycerine
greekman
- 27 Jul 2009 16:50
- 119 of 290
No wonder the public feel mislead.
Government virus expert paid 116k by Tamiflu vaccine makers
By David Derbyshire
Last updated at 1:24 AM on 27th July 2009
Sir Roy, 61, who was unavailable for comment yesterday, earned 116,000 at GSK last year, at least a quarter of which he received in shares.
http://www.dailymail.co.uk/news/article-1202389/Government-virus-expert-paid-116k-Tamiflu-vaccine-makers.html
Well done...The Daily Mail
Government virus expert paid 116k by Tamiflu vaccine makers
By David Derbyshire
Last updated at 1:24 AM on 27th July 2009
Sir Roy, 61, who was unavailable for comment yesterday, earned 116,000 at GSK last year, at least a quarter of which he received in shares.
http://www.dailymail.co.uk/news/article-1202389/Government-virus-expert-paid-116k-Tamiflu-vaccine-makers.html
Well done...The Daily Mail
kimoldfield
- 27 Jul 2009 18:15
- 120 of 290
Greek, nothing surprises me anymore! The Government would have been aware of this; I wonder how many GSK shares GB & AD etc have?!
greekman
- 28 Jul 2009 07:57
- 121 of 290
But that would be hinting that like most other politicians they are corrupt, and we can't have that can we.
kimoldfield
- 28 Jul 2009 08:04
- 122 of 290
Not at all! ;o)
greekman
- 28 Jul 2009 08:15
- 123 of 290
Another collaboration deal.
Amgen and GlaxoSmithKline to collaborate on Denosumab for postmenopausal osteoporosis
28. July 2009 01:56
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
http://www.news-medical.net/news/20090728/Amgen-and-GlaxoSmithKline-to-collaborate-on-Denosumab-for-postmenopausal-osteoporosis.aspx
Amgen and GlaxoSmithKline to collaborate on Denosumab for postmenopausal osteoporosis
28. July 2009 01:56
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
http://www.news-medical.net/news/20090728/Amgen-and-GlaxoSmithKline-to-collaborate-on-Denosumab-for-postmenopausal-osteoporosis.aspx
greekman
- 04 Aug 2009 18:12
- 124 of 290
RNS.
Re Vaccine order increase.
This now brings the total number of doses ordered for GSK's adjuvanted vaccine to 291 million. Discussions continue with governments for further supplies of the vaccine.
GSK's proposed donation of 50 million doses of the H1N1 vaccine to the WHO.
The 50 million doses is further good PR for GSK following Witty's formula.
Re Vaccine order increase.
This now brings the total number of doses ordered for GSK's adjuvanted vaccine to 291 million. Discussions continue with governments for further supplies of the vaccine.
GSK's proposed donation of 50 million doses of the H1N1 vaccine to the WHO.
The 50 million doses is further good PR for GSK following Witty's formula.
greekman
- 05 Aug 2009 12:12
- 125 of 290
A few more figures.
Figures in the media are now predicting a boost to GSK of 1.8 billion, with up to 3 billion if further orders flow in from those counties who have not yet signed deals with vaccine producing companies.
This month Glaxo are to start clinical trials, with the first supplies set for delivery in September.
It is the clinical trial bit that will hold the sp back for a while, but Glaxo appear to have the lead, in supply contracts.
Figures in the media are now predicting a boost to GSK of 1.8 billion, with up to 3 billion if further orders flow in from those counties who have not yet signed deals with vaccine producing companies.
This month Glaxo are to start clinical trials, with the first supplies set for delivery in September.
It is the clinical trial bit that will hold the sp back for a while, but Glaxo appear to have the lead, in supply contracts.
Falcothou - 05 Aug 2009 13:14 - 126 of 290
I think the strengthening cable isn't helping either, some anticipating 1.75,almost worth hedging with a long cable position!
skinny
- 21 Aug 2009 16:42
- 127 of 290
Finally a close above 12.
Falcothou - 21 Aug 2009 20:19 - 128 of 290
I think glaxo is one of the few equities that deserve to be going up roll on 50 what it would be valued at if in a different sector
greekman
- 09 Sep 2009 17:42
- 129 of 290
LONDON (SHARECAST) - The Centers for Disease Control and Prevention (CDC) issued new guidelines for the use of antivirals in the treatment of flu on Tuesday, which should boost revenues drugs giant GlaxoSmithKline (GSK) receives from its Relenza flu treatment.
Broker Panmure Gordon is forecasting Relenza revenues of 700m for 2009, and expects this figure to rise to 1bn in 2010 before sliding back towards 250m per annum from 2011 onwards.
http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=2995520
Broker Panmure Gordon is forecasting Relenza revenues of 700m for 2009, and expects this figure to rise to 1bn in 2010 before sliding back towards 250m per annum from 2011 onwards.
http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=2995520
greekman
- 11 Sep 2009 16:28
- 130 of 290
An AFX worth reporting .
Japan's health ministry is set to buy enough H1N1 flu vaccine for nearly 50 million people from British drug maker GlaxoSmithKline and Switzerland's Novartis, a Japanese newspaper reported on Friday.
The country can produce enough vaccine for about 18 million people but the government hopes to push that figure close to 70 million with the added imports, the Asahi newspaper said.
The government will spend about 100 billion yen ($1.1 billion) on the Glaxo vaccine.
Japan's health ministry is set to buy enough H1N1 flu vaccine for nearly 50 million people from British drug maker GlaxoSmithKline and Switzerland's Novartis, a Japanese newspaper reported on Friday.
The country can produce enough vaccine for about 18 million people but the government hopes to push that figure close to 70 million with the added imports, the Asahi newspaper said.
The government will spend about 100 billion yen ($1.1 billion) on the Glaxo vaccine.
skinny
- 28 Sep 2009 14:58
- 131 of 290
Just closed my position from a couple of months ago - so other holders should expect a sharp rise now :-)
skinny
- 06 Oct 2009 07:16
- 132 of 290
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
The company today provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine.
On the 4th August, GSK confirmed that it had contracts in place to supply 291 million doses of the vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million.
Since that date, 22 government orders have been agreed to supply a further 149 million doses of the vaccine. This now brings the total number of doses ordered for GSK's pandemic vaccines to 440 million. Discussions continue with governments for further supplies.
First supplies of the vaccine will be shipped to governments during the week commencing 5th October. Shipments of the vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010.
The vaccine deliveries are contingent on a number of factors including government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling as well as testing required by reference laboratories.
GSK will continue to provide regular updates to governments relating to delivery schedules to support them in planning their vaccination programmes.
Further information on GSK's development of vaccines to protect against pandemic (H1N1) 2009, including explanation of the development process and background information on adjuvants is available on: http://www.gsk.com/media/pandemic-flu.htm
GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
The company today provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine.
On the 4th August, GSK confirmed that it had contracts in place to supply 291 million doses of the vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million.
Since that date, 22 government orders have been agreed to supply a further 149 million doses of the vaccine. This now brings the total number of doses ordered for GSK's pandemic vaccines to 440 million. Discussions continue with governments for further supplies.
First supplies of the vaccine will be shipped to governments during the week commencing 5th October. Shipments of the vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010.
The vaccine deliveries are contingent on a number of factors including government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling as well as testing required by reference laboratories.
GSK will continue to provide regular updates to governments relating to delivery schedules to support them in planning their vaccination programmes.
Further information on GSK's development of vaccines to protect against pandemic (H1N1) 2009, including explanation of the development process and background information on adjuvants is available on: http://www.gsk.com/media/pandemic-flu.htm
greekman
- 25 Nov 2009 18:58
- 133 of 290
A 16mill buy (well it is recorded as such, so I hope it is) gone through during the auction. Thats around 200mill, big money for anyone. No doubt we will see a RNS within a couple of days as to which institution was involved.
Someone know something we don't?
Someone know something we don't?
Falcothou - 25 Nov 2009 19:55 - 134 of 290
Hopefully not Buffett cashing in
greekman
- 26 Nov 2009 07:11
- 135 of 290
Via AFX.
WASHINGTON, Nov 25 (Reuters) - The U.S. Food and Drug Administration on Wednesday:
SAID THE AGENCY HAD CANCELED ITS DECEMBER 16 ADVISORY PANEL REVIEW OF GLAXOSMITHKLINE PLC'S BREAST CANCER DRUG TYKERB
SAID IT CANCELED THE PANEL'S REVIEW OF A NEW USE FOR TYKERB BECAUSE ISSUES IN QUESTION "HAVE BEEN RESOLVED"
POSTED THE ANNOUNCEMENT ON ITS WEBSITE AT HTTP://WWW.FDA.GOV/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ONCOLOGICDRUGSADVISORYCOMMITTEE/UCM192036.HTM
FDA HAS SAID THE COMPANY WAS PROPOSING NEW USE OF THE DRUG IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF HORMONE SENSITIVE ADVANCED OR METASTATIC BREAST CANCER (Company news desk in Washington; +1 202 898 8400,
WASHINGTON, Nov 25 (Reuters) - The U.S. Food and Drug Administration on Wednesday:
SAID THE AGENCY HAD CANCELED ITS DECEMBER 16 ADVISORY PANEL REVIEW OF GLAXOSMITHKLINE PLC'S BREAST CANCER DRUG TYKERB
SAID IT CANCELED THE PANEL'S REVIEW OF A NEW USE FOR TYKERB BECAUSE ISSUES IN QUESTION "HAVE BEEN RESOLVED"
POSTED THE ANNOUNCEMENT ON ITS WEBSITE AT HTTP://WWW.FDA.GOV/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ONCOLOGICDRUGSADVISORYCOMMITTEE/UCM192036.HTM
FDA HAS SAID THE COMPANY WAS PROPOSING NEW USE OF THE DRUG IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF HORMONE SENSITIVE ADVANCED OR METASTATIC BREAST CANCER (Company news desk in Washington; +1 202 898 8400,
skinny
- 04 Feb 2010 12:25
- 136 of 290
Final Results.
Summary
Full year sales growth of 3% with successful delivery of diversification strategy
Consumer Healthcare (+7%), Emerging Markets (+20%), Japan (+22%)
Sales from 'white pill/western markets': 30% of 2009 full year sales (36% in 2008)
Continued new product delivery
Total of 12 approvals and 11 new product filings in 2009
6 NME/vaccine launch opportunities in next 18 months
Sustained R&D productivity with ~30 assets in late-stage development
New R&D model fully operational
Further actions to improve R&D returns
Proposed reduction to R&D infrastructure
Neuroscience research to focus on neurodegeneration and neuroinflammation; proposed cessation of discovery research in selected areas including depression and pain
New rare diseases unit to be established
Restructuring programme expanded; additional savings of 500 million by 2012
R&D (50%); SG&A (50%)
70% of savings to enhance profitability; 30% to be reinvested
Expected additional charges of 0.9 billion
2009 EPS before major restructuring of 121.2p, includes:
Q4 gain relating to formation of ViiV Healthcare of 296 million (4.2p of EPS)
Q4 legal charge 392 million (5.6p of EPS), with increased provisions for existing cases
Increased 2009 dividend of 61p, up 7% (Q4: 18p, up 6%)
Summary
Full year sales growth of 3% with successful delivery of diversification strategy
Consumer Healthcare (+7%), Emerging Markets (+20%), Japan (+22%)
Sales from 'white pill/western markets': 30% of 2009 full year sales (36% in 2008)
Continued new product delivery
Total of 12 approvals and 11 new product filings in 2009
6 NME/vaccine launch opportunities in next 18 months
Sustained R&D productivity with ~30 assets in late-stage development
New R&D model fully operational
Further actions to improve R&D returns
Proposed reduction to R&D infrastructure
Neuroscience research to focus on neurodegeneration and neuroinflammation; proposed cessation of discovery research in selected areas including depression and pain
New rare diseases unit to be established
Restructuring programme expanded; additional savings of 500 million by 2012
R&D (50%); SG&A (50%)
70% of savings to enhance profitability; 30% to be reinvested
Expected additional charges of 0.9 billion
2009 EPS before major restructuring of 121.2p, includes:
Q4 gain relating to formation of ViiV Healthcare of 296 million (4.2p of EPS)
Q4 legal charge 392 million (5.6p of EPS), with increased provisions for existing cases
Increased 2009 dividend of 61p, up 7% (Q4: 18p, up 6%)
Falcothou - 04 Feb 2010 12:54 - 137 of 290
18p is the important bit
skinny
- 05 Feb 2010 11:58
- 138 of 290
I bought back in this morning @1208. Looking for limited downside and a 5% return with dividend increase.
greekman
- 05 Feb 2010 16:53
- 139 of 290
Director Buys.
Well MR Witty and Bicknell appear confident.
Well MR Witty and Bicknell appear confident.
partridge
- 05 Feb 2010 21:16
- 140 of 290
Excellent cash generation encourages me to believe that the dividend is safe for the foreseeable future and sure as hell beats bank deposit rates. Have held for many years in PEP/ISA, occasionally top slicing or adding some more and still I believe a solid long term performer, but always DYOR.
greekman
- 07 Feb 2010 13:24
- 141 of 290
Excellent write up in The Sunday Telegraph, which includes an interview with Andrew Witty.
skinny
- 10 Feb 2010 07:13
- 142 of 290
hjs - 10 Feb 2010 10:37 - 143 of 290
Ex div today?
skinny
- 10 Feb 2010 10:41
- 144 of 290
Yes!
greekman
- 10 Feb 2010 18:03
- 145 of 290
Business newswire obviously have their ear to the ground.
Pharmaceutical heavyweight GlaxoSmithKline was a major casualty, down 17p at 1,201.5p after yesterday's announcement that it plans to close a research unit in Essex.
No mention of the share being ex div today, which to me was the real reason.
Pharmaceutical heavyweight GlaxoSmithKline was a major casualty, down 17p at 1,201.5p after yesterday's announcement that it plans to close a research unit in Essex.
No mention of the share being ex div today, which to me was the real reason.
Balerboy
- 10 Feb 2010 21:08
- 146 of 290
8p div i think, not worth the drop in sp which can happen. was lucky with IMT.
skinny
- 11 Feb 2010 07:16
- 147 of 290
BB - 18p Dividend.
greekman
- 11 Feb 2010 07:37
- 148 of 290
The drop was about the same percentage as the dividend of 18p, so yesterdays loss meant a static price. As the yield on the total years divi is 5.06%, one of the best in the market, coupled with the strength of the company and its future prospects, I consider Glaxo to be one of the safest (including the div) companies on the market.
skinny
- 11 Feb 2010 07:40
- 149 of 290
Hear Hear!
Balerboy
- 11 Feb 2010 07:49
- 150 of 290
i stand corrected..BB
skinny
- 22 Feb 2010 09:47
- 151 of 290
Galapagos Identifies New Candidate Drug For Arthritis
BRUSSELS (Dow Jones)
Belgian drug discovery company Galapagos NV (GLPG.BT) Monday said it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline (GSK). The company also reached milestones for other compounds in the alliance, which trigger cash payments totaling EUR5.7 million to Galapagos.
MAIN FACTS:
-This latest preclinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate against a novel drug target from its proprietary platform. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials early 2011.
BRUSSELS (Dow Jones)
Belgian drug discovery company Galapagos NV (GLPG.BT) Monday said it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline (GSK). The company also reached milestones for other compounds in the alliance, which trigger cash payments totaling EUR5.7 million to Galapagos.
MAIN FACTS:
-This latest preclinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate against a novel drug target from its proprietary platform. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials early 2011.
greekman
- 23 Feb 2010 10:18
- 152 of 290
We know this paragraph.
The US Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline Plc's diabetes drug Avandia but has not reached any new conclusions, the agency said on Monday.
But I didn't know this (Did I miss it earlier).
The FDA will hold a public meeting in July 2010 to discuss the risks and benefits of the drug, but said in the meantime doctors and patients should continue to use Avandia as directed.
So Avandia is in limbo till at least July.
All the evidence for and against is out there so why the 5 month delay.
Jobs-worthies, justifying their existence!
The US Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline Plc's diabetes drug Avandia but has not reached any new conclusions, the agency said on Monday.
But I didn't know this (Did I miss it earlier).
The FDA will hold a public meeting in July 2010 to discuss the risks and benefits of the drug, but said in the meantime doctors and patients should continue to use Avandia as directed.
So Avandia is in limbo till at least July.
All the evidence for and against is out there so why the 5 month delay.
Jobs-worthies, justifying their existence!
greekman
- 25 Feb 2010 08:53
- 153 of 290
Sold out today. Not because I have lost confidence in GSK, but feel the market as a whole is in for a double dip due to the financial situation being worse than it looks on the surface. Mainly the PIGS situation and the world finances in general.
So probably won't post again on here for a while, but will continue to watch/read with interest.
Good luck to all still in.
So probably won't post again on here for a while, but will continue to watch/read with interest.
Good luck to all still in.
skinny
- 26 Mar 2010 07:41
- 154 of 290
Notifiable Share Interest in JCR Pharmaceuticals Co., Limited
GlaxoSmithKline plc ("GSK") announces that, on 26 March 2010, GSK exercised
stock acquisition rights at an exercise price of JPY650 per share to acquire
1,560,000 Common shares of JCR Pharmaceuticals Co., Limited ("JCR"), a
pharmaceutical company located in Japan and whose shares are traded on the Osaka
Stock Exchange. The details of this transaction have been disclosed in an
announcement issued by JCR to the Osaka Stock Exchange on 26 March 2010.
Following this transaction, GSK's interest, which is held by its wholly owned
subsidiary, Glaxo Group Limited, has increased from 12.05% to 16.73% of the
outstanding Common shares of JCR, making GSK the largest shareholder of JCR.
GSK's total holding represents 16.92% of the total voting rights in JCR. The
details of this transaction have been disclosed in an announcement issued by JCR
to the Osaka Stock Exchange on 26 March 2010.
GlaxoSmithKline plc ("GSK") announces that, on 26 March 2010, GSK exercised
stock acquisition rights at an exercise price of JPY650 per share to acquire
1,560,000 Common shares of JCR Pharmaceuticals Co., Limited ("JCR"), a
pharmaceutical company located in Japan and whose shares are traded on the Osaka
Stock Exchange. The details of this transaction have been disclosed in an
announcement issued by JCR to the Osaka Stock Exchange on 26 March 2010.
Following this transaction, GSK's interest, which is held by its wholly owned
subsidiary, Glaxo Group Limited, has increased from 12.05% to 16.73% of the
outstanding Common shares of JCR, making GSK the largest shareholder of JCR.
GSK's total holding represents 16.92% of the total voting rights in JCR. The
details of this transaction have been disclosed in an announcement issued by JCR
to the Osaka Stock Exchange on 26 March 2010.
skinny
- 28 Apr 2010 17:05
- 155 of 290
1st Quarter results.
GlaxoSmithKline 1Q Net Profit +17, Beats Views
By Sten Stovall
Of DOW JONES NEWSWIRES
LONDON (Dow Jones)
GlaxoSmithKline PLC (GSK, GSK.LN) Wednesday beat forecasts with a 17% rise in first-quarter net profit, boosted by sales of its pandemic flu and hepatitis vaccines, its top selling asthma treatment Advair and newer medicines like breast cancer pill Tykerb, as well as further expansion in emerging markets.
Andrew Witty, Glaxo's chief executive officer, said in a statement: "Our sales growth is multi-sourced with good performances in our Pharmaceuticals business, driven by vaccines, respiratory and dermatology products and in our Consumer Healthcare business. In all of these areas, sales were especially dynamic across emerging markets where we continue to gain market share."
GlaxoSmithKline no longer provides a specific numerical outlook.
In the three months to March 31, net profit rose to GBP1.56 billion from GBP1.33 billion in the same period a year earlier. A poll of nine analysts had foreseen net profit rising to GBP1.51 billion.
Sales climbed 8.7% to GBP7.36 billion, beating analyst forecasts of GBP7.28 billion for the latest quarter.
Earnings per share for the first quarter before major restructuring increased 16% from a year earlier, to 30.7 pence.
Glaxo shares rose after the update and, at 1119 GMT, were trading up 1.4% or 17p at 1,231 pence, in a lower London market. The stock has gained around 15% in value over the last 12 months.
GlaxoSmithKline, unlike many of its rivals, has already undergone the bulk of its patent expiries. Under CEO Witty, the company has diversified itself via revamps and acquisitions and is now emerging strongly with a solid pipeline--led by its new autoimmune disease drug Benlysta--and is increasingly focused on growth, particularly in emerging markets and Japan.
GlaxoSmithKline 1Q Net Profit +17, Beats Views
By Sten Stovall
Of DOW JONES NEWSWIRES
LONDON (Dow Jones)
GlaxoSmithKline PLC (GSK, GSK.LN) Wednesday beat forecasts with a 17% rise in first-quarter net profit, boosted by sales of its pandemic flu and hepatitis vaccines, its top selling asthma treatment Advair and newer medicines like breast cancer pill Tykerb, as well as further expansion in emerging markets.
Andrew Witty, Glaxo's chief executive officer, said in a statement: "Our sales growth is multi-sourced with good performances in our Pharmaceuticals business, driven by vaccines, respiratory and dermatology products and in our Consumer Healthcare business. In all of these areas, sales were especially dynamic across emerging markets where we continue to gain market share."
GlaxoSmithKline no longer provides a specific numerical outlook.
In the three months to March 31, net profit rose to GBP1.56 billion from GBP1.33 billion in the same period a year earlier. A poll of nine analysts had foreseen net profit rising to GBP1.51 billion.
Sales climbed 8.7% to GBP7.36 billion, beating analyst forecasts of GBP7.28 billion for the latest quarter.
Earnings per share for the first quarter before major restructuring increased 16% from a year earlier, to 30.7 pence.
Glaxo shares rose after the update and, at 1119 GMT, were trading up 1.4% or 17p at 1,231 pence, in a lower London market. The stock has gained around 15% in value over the last 12 months.
GlaxoSmithKline, unlike many of its rivals, has already undergone the bulk of its patent expiries. Under CEO Witty, the company has diversified itself via revamps and acquisitions and is now emerging strongly with a solid pipeline--led by its new autoimmune disease drug Benlysta--and is increasingly focused on growth, particularly in emerging markets and Japan.
skinny
- 03 Feb 2011 12:10
- 156 of 290
Final Results.
Unaudited Preliminary Results Announcement for the year ended 31st December 2010
Strategic progress drives positive underlying sales growth*,
increasing pipeline potential and improved cash generation
Increased dividend and new long-term share buy-back
programme enhance returns to shareholders
Unaudited Preliminary Results Announcement for the year ended 31st December 2010
Strategic progress drives positive underlying sales growth*,
increasing pipeline potential and improved cash generation
Increased dividend and new long-term share buy-back
programme enhance returns to shareholders
skinny
- 18 Feb 2011 16:08
- 157 of 290
EU agency concerned by narcolepsy link to GSK shot
Reuters) - European drugs regulators are continuing a safety review of GlaxoSmithKline's H1N1 flu vaccine Pandemrix and said on Friday they were concerned by further reports of possible links to narcolepsy, a rare sleep disorder.
Reuters) - European drugs regulators are continuing a safety review of GlaxoSmithKline's H1N1 flu vaccine Pandemrix and said on Friday they were concerned by further reports of possible links to narcolepsy, a rare sleep disorder.
dreamcatcher
- 22 Oct 2011 21:53
- 158 of 290
News from another sector that is arguably undervalued pharmaceutical company Glaxosmithkline report on their third-quarter performances on Wednesday .
Has been out of favour, due to a number of drugs reaching the ends of their patent lives, fears of slowdowns in development pipelines, and increasing competition from developing countries -- although GlaxoSmithKline shares have staged something of a recovery in recent months.
Glaxo shares, at just under 14, on a forward P/E of 12 and offering a 5% yield.
Has been out of favour, due to a number of drugs reaching the ends of their patent lives, fears of slowdowns in development pipelines, and increasing competition from developing countries -- although GlaxoSmithKline shares have staged something of a recovery in recent months.
Glaxo shares, at just under 14, on a forward P/E of 12 and offering a 5% yield.
skinny
- 26 Oct 2011 12:34
- 159 of 290
3rd Quarter Results.
GSK delivers strong Q3 performance with underlying sales growth* of 6% and reported sales
growth of 3%
* EPS 28.5p +1% before major restructuring*
* Dividend +6% to 17p; 2011 share buyback expectations
increased to up to GBP2.3 billion
GSK delivers strong Q3 performance with underlying sales growth* of 6% and reported sales
growth of 3%
* EPS 28.5p +1% before major restructuring*
* Dividend +6% to 17p; 2011 share buyback expectations
increased to up to GBP2.3 billion
midknight
- 08 Dec 2011 16:20
- 160 of 290
It's taken a long time but GSK seems to be firmly (?) in the saddle
now, I hope!
now, I hope!
skinny
- 09 Jan 2012 08:32
- 161 of 290
dreamcatcher
- 05 Feb 2012 19:12
- 162 of 290
Tuesday February 7
• GlaxoSmithKline will update the market on its annual results. Britain’s biggest drug maker is expected to post revenues of £27.6bn compared with £28.4bn last time and profits of £8.4bn compared with £4.5bn the previous year, when Glaxo’s earnings were hit by a £2.2bn legal charge in the final quarter. Investors will be looking for an update on how Glaxo is allocating funding to its 38 “discovery performance units”, having held a Dragons’ Den-style review to find its most promising research projects.
• GlaxoSmithKline will update the market on its annual results. Britain’s biggest drug maker is expected to post revenues of £27.6bn compared with £28.4bn last time and profits of £8.4bn compared with £4.5bn the previous year, when Glaxo’s earnings were hit by a £2.2bn legal charge in the final quarter. Investors will be looking for an update on how Glaxo is allocating funding to its 38 “discovery performance units”, having held a Dragons’ Den-style review to find its most promising research projects.
skinny
- 07 Feb 2012 14:27
- 163 of 290
Final Results.
Unaudited Preliminary Results Announcement for the year ended 31 December 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
2011 underlying sales +4% (reported -3%); EPS before major restructuring* 114.1p; total dividends of 75p.
Unaudited Preliminary Results Announcement for the year ended 31 December 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
2011 underlying sales +4% (reported -3%); EPS before major restructuring* 114.1p; total dividends of 75p.
skinny
- 22 Mar 2012 06:54
- 164 of 290
Glaxo invests £500m in UK and builds new factory
Drugmaker GlaxoSmithKline has said it will invest £500m in manufacturing in the UK, including building a new factory in Ulverston, Cumbria.
The investments could create up to 1,000 new jobs, Glaxo said. The biopharmaceutical facility will be its first new UK factory for 40 years.
Glaxo said it was "one of the largest commitments to the UK life-sciences sector in recent years".
Drugmaker GlaxoSmithKline has said it will invest £500m in manufacturing in the UK, including building a new factory in Ulverston, Cumbria.
The investments could create up to 1,000 new jobs, Glaxo said. The biopharmaceutical facility will be its first new UK factory for 40 years.
Glaxo said it was "one of the largest commitments to the UK life-sciences sector in recent years".
skinny
- 25 Apr 2012 12:24
- 165 of 290
1st Quarter Results.
GSK reports sales growth (+2% CER), further R&D delivery, operational leverage and continued
returns to shareholders
- Core* EPS 27.3p (+7%)
* Dividend up 6% to 17p; total 2012 share buyback now
expected to be GBP2-GBP2.5 billion including non-core
OTC disposal proceeds
GSK reports sales growth (+2% CER), further R&D delivery, operational leverage and continued
returns to shareholders
- Core* EPS 27.3p (+7%)
* Dividend up 6% to 17p; total 2012 share buyback now
expected to be GBP2-GBP2.5 billion including non-core
OTC disposal proceeds
skinny
- 12 Jun 2012 07:03
- 166 of 290
GSK signs worldwide acquisition for Toctino
Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily oral retinoid and the only prescription medicine specifically approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults. It is commercially available in 14 countries, approved in an additional 15 countries, and is in a Phase 3 trial in the US. In 2011, worldwide sales of Toctino were £22m.
Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily oral retinoid and the only prescription medicine specifically approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults. It is commercially available in 14 countries, approved in an additional 15 countries, and is in a Phase 3 trial in the US. In 2011, worldwide sales of Toctino were £22m.
skinny
- 24 Apr 2013 14:08
- 167 of 290
1st Quarter Results
Summary
■ Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons:
- Sales +2% excluding divestments (primarily Vesicare and non-core OTC brands)
- Pharmaceuticals and Vaccines sales -2%: US -6% (+4% excl. Vesicare with strong respiratory and oncology performances), Europe -3%, EMAP +8%, Japan -8% (+11% excl. Cervarix)
- Consumer Healthcare +1% (+6% excluding divestments)
■ Continued R&D pipeline progress:
- Positive FDA Advisory Committee recommendation for use of Breo Ellipta in treatment of COPD; FDA Action date 12 May
- MEK monotherapy, MEK/BRAF combination use and albiglutide filed in Europe; dolutegravir granted Priority Review in US; Anoro Ellipta filed in Japan
■ Continued delivery of financial efficiencies, strong cash generation and returns to shareholders:
- Adjusted net cash inflow from operating activities of £1.4 billion (Q1 2012: £1.1 billion)
- Initial phases of new major change programme, including European restructuring, progressing well
- Q1 core tax rate 22.4% reflecting benefit of US R&D tax credit; continue to expect full year core tax rate of around 24%
- Q1 dividend: 18p, +6%; continuing to target share repurchases for the year at £1-2 billion
■ Further measures to drive strategic focus and improve growth profile:
- Strategic review of Lucozade and Ribena completed; decision to pursue divestment subject to appropriate value realisation
- Pharmaceutical tail brands (with 2012 sales of around £3 billion from over 50 brands) to be formed into a Global Established Products portfolio; co-ordinated and reported separately from January 2014
■ 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)
Summary
■ Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons:
- Sales +2% excluding divestments (primarily Vesicare and non-core OTC brands)
- Pharmaceuticals and Vaccines sales -2%: US -6% (+4% excl. Vesicare with strong respiratory and oncology performances), Europe -3%, EMAP +8%, Japan -8% (+11% excl. Cervarix)
- Consumer Healthcare +1% (+6% excluding divestments)
■ Continued R&D pipeline progress:
- Positive FDA Advisory Committee recommendation for use of Breo Ellipta in treatment of COPD; FDA Action date 12 May
- MEK monotherapy, MEK/BRAF combination use and albiglutide filed in Europe; dolutegravir granted Priority Review in US; Anoro Ellipta filed in Japan
■ Continued delivery of financial efficiencies, strong cash generation and returns to shareholders:
- Adjusted net cash inflow from operating activities of £1.4 billion (Q1 2012: £1.1 billion)
- Initial phases of new major change programme, including European restructuring, progressing well
- Q1 core tax rate 22.4% reflecting benefit of US R&D tax credit; continue to expect full year core tax rate of around 24%
- Q1 dividend: 18p, +6%; continuing to target share repurchases for the year at £1-2 billion
■ Further measures to drive strategic focus and improve growth profile:
- Strategic review of Lucozade and Ribena completed; decision to pursue divestment subject to appropriate value realisation
- Pharmaceutical tail brands (with 2012 sales of around £3 billion from over 50 brands) to be formed into a Global Established Products portfolio; co-ordinated and reported separately from January 2014
■ 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)
skinny
- 24 Apr 2013 14:09
- 168 of 290
GSK puts Lucozade and Ribena drink brands up for sale
LONDON | Wed Apr 24, 2013 1:45pm BST
(Reuters) - GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds and focus its consumer health business on global products.
The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3 percent from a year ago.
LONDON | Wed Apr 24, 2013 1:45pm BST
(Reuters) - GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds and focus its consumer health business on global products.
The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3 percent from a year ago.
skinny
- 11 Jul 2013 07:23
- 169 of 290
China security ministry says GSK executives confess to crimes
BEIJING | Thu Jul 11, 2013 7:14am BST
(Reuters) - Executives of British drug maker GlaxoSmithKline Plc in China have confessed to charges of bribery and tax law violations after initial questioning by Chinese police, China's security ministry said on Thursday.
The company is suspected of offering bribes to government officials, medical associations, hospitals and doctors to boost sales and prices, the ministry said in a statement on its website.
GSK is also suspected of using fake receipts in unspecified tax law violations, the ministry said.
BEIJING | Thu Jul 11, 2013 7:14am BST
(Reuters) - Executives of British drug maker GlaxoSmithKline Plc in China have confessed to charges of bribery and tax law violations after initial questioning by Chinese police, China's security ministry said on Thursday.
The company is suspected of offering bribes to government officials, medical associations, hospitals and doctors to boost sales and prices, the ministry said in a statement on its website.
GSK is also suspected of using fake receipts in unspecified tax law violations, the ministry said.
skinny
- 05 Sep 2013 07:22
- 170 of 290
MAGE A-3 Phase III DERMA Study Results
GlaxoSmithKline plc (LSE:GSK) today announced that an independent analysis of the DERMAi study, a Phase III randomised, blinded, placebo-controlled trial of the MAGE-A3 cancer immunotherapeuticii showed that the study did not meet its first co-primary endpoint as it did not significantly extend disease-free survival (DFSiii) when compared to placebo in the MAGE-A3 positive population.
GlaxoSmithKline plc (LSE:GSK) today announced that an independent analysis of the DERMAi study, a Phase III randomised, blinded, placebo-controlled trial of the MAGE-A3 cancer immunotherapeuticii showed that the study did not meet its first co-primary endpoint as it did not significantly extend disease-free survival (DFSiii) when compared to placebo in the MAGE-A3 positive population.
skinny
- 23 Oct 2013 12:30
- 171 of 290
midknight
- 23 Apr 2014 11:38
- 172 of 290
April 23 - After the hallabaloo:
JP Morgan Cazenove: Neutral - Reiteration
Credit Suisse: Underperform - TP held at 1600p - Reiteration
UBS: Neutral - TP held at 1500p - Reiteration
Deutsche: Hold - TP raised from 1620p to 1750p - Reiteration
Societe Generale: Buy - TP held at 2088p - Reiteration
JP Morgan Cazenove: Neutral - Reiteration
Credit Suisse: Underperform - TP held at 1600p - Reiteration
UBS: Neutral - TP held at 1500p - Reiteration
Deutsche: Hold - TP raised from 1620p to 1750p - Reiteration
Societe Generale: Buy - TP held at 2088p - Reiteration
midknight
- 16 Jun 2014 15:58
- 173 of 290
June 16: Societe Generale: Buy - TP: 2100p.
Ages since I saw such an upbeat TP.
Ages since I saw such an upbeat TP.
midknight
- 30 Jun 2014 10:14
- 174 of 290
midknight
- 02 Jul 2014 12:28
- 176 of 290
July 2: Deutsche: Hold - TP: 1630p.
midknight
- 08 Jul 2014 12:31
- 178 of 290
July 7: Credit Suisse: Underperform; TP: 1600p
.
.
midknight
- 14 Jul 2014 11:51
- 179 of 290
July 14:
Jefferies reiterates: Hold - TP down from 1610 to 1460p.
Credit Suissse reiterates: Underperform - TP retained: 1600p.
Jefferies reiterates: Hold - TP down from 1610 to 1460p.
Credit Suissse reiterates: Underperform - TP retained: 1600p.
midknight
- 15 Jul 2014 12:02
- 180 of 290
July 15: UBS: reiterates Neutral - TP: 1500p.
goldfinger
- 31 Jul 2014 16:53
- 182 of 290
GlaxoSmithKline good value at 1428p
BY ROBERT SUTHERLAND SMITH | TUESDAY 29 JULY 2014
The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?
The results for the first half of the current year were dire. With turnover down 12% should be attribute that to the simple strength of Sterling. Evidently not; because when you take that into account revenue still fell 3% in constant exchange value terms. Was the full impact of generic competition for its main drugs; or the fact that having been caught up in accusations of bribing doctors in China to prescribe its drugs a head of those of competitors? The company has reportedly now made drastic reforms to its selling and marketing policies my breaking such a link to sales personnel pay. It is impossible to judge from outside the company.
The annual dividend last year cost £3.7 billion. It is good to see that balance sheet end year cash has been rising for £3.9 billion the previous year to £5.2 billion last year. So in the meantime, there appears to be sufficient cash in the balance sheet to finance dividends, though cash generation has to be an ever ongoing process. Glancing at the market consensus estimates, I see that there is still a clear expectation of a progressive dividend policy with consensus of analysts expecting dividends to increase 4% this year and about 4.4% next year putting, Glaxo shares on prospective annual dividend yields of an estimated 5.7% for this year and 6.0% for next year. It is to be noted that the Q2 dividend payment of 19p for Q2 was reportedly 6% up on the amount paid last year.
The market in its consensus forecasts is also estimating a 13% fall in earnings this year but an increase of 8% next year. When reading the report you will see that the management speaks confidently about its drug development programme referring to 40 near approval entities in late stage development. It may not have a cure for the Ebola virus but it will be bring much needed new drusg to market. It adds that 30% of its R&D assets have, in the view of the company, the potential to “first class” in the companies chosen areas of therapeutic medicines. Furthermore, the joint venture with Novartis in vaccines which the two companies have put intellectual property and research and development assets, has the potential, says GSK, to grow around half of the Group’s future revenue. In the final analysis, the company has now openly discussed a possible future sale of its consumer, over the counter health care business, if necessary, with the caveat that retaining it provides scales of economy for the business in the important emerging markets. It does not sound as though they are rushing to do that.
It strikes me that the perceived three year support line on the share price chart sits nicely with a high yield together suggesting that the shares look good value in dividend yield terms after a period of bad news and particularly poor results.
- See more at: http://www.shareprophets.advfn.com/views/6849/glaxosmithkline-good-value-at-1428p#sthash.ACUhuWnY.dpuf
goldfinger
- 02 Aug 2014 14:46
- 183 of 290
August 1, 2014 6:11 pm
GlaxoSmithKline vulnerable to Pfizer bid after price slump
Bryce ElderBy Bryce ElderAuthor alerts
GlaxoSmithKline’s fall to an 18-month low might make the drugmaker vulnerable, according to Berenberg analysts.
A 20 per cent slump over the past year has left GSK’s market value lower than Pfizer’s rejected $120bn offer for AstraZeneca, Berenberg highlighted. “GSK may just be too large for Pfizer to handle, but as a plan B it has some merits,” the broker told clients.
As well as benefiting from GSK’s low 20 per cent tax rate, Pfizer could create a world-class vaccines business via a takeover, Berenberg argued. It also noted that GSK and Pfizer already collaborate on ViiV Healthcare, an HIV joint venture.
Assuming a 45 per cent premium to Glaxo’s current valuation, Pfizer would need to find $74bn in cash to fund a $164bn offer for GSK, said the broker, adding: “This is perhaps a stretch, but not totally unrealistic.”
Pfizer was seen as unlikely to be interested in GSK’s consumer products joint venture with Novartis, which was agreed in April as part of a $20bn asset swap. Oncology, which GSK is shedding, would be a better fit with Pfizer but would also be a point of competitive overlap, said the broker.
GSK closed down 1.4 per cent at £14.17, having rallied from a session low of £14.03.
goldfinger
- 06 Aug 2014 08:11
- 184 of 290
Neil Woodford: GlaxoSmithKline's troubles are only temporary
Renowned fund manager gives embattled drug giant a vote of confidence
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11013056/Neil-Woodford-GlaxoSmithKlines-troubles-are-only-temporary.html
Renowned fund manager gives embattled drug giant a vote of confidence
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11013056/Neil-Woodford-GlaxoSmithKlines-troubles-are-only-temporary.html
goldfinger
- 07 Aug 2014 02:42
- 185 of 290
GlaxoSmithKline plc Offers 40% Upside For Canny Investors
By Alessandro Pasetti - Wednesday, 6 August, 2014
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares are down 9.6% in 2014. In the last twelve months of trading, they have lost 14.7% of value. If Glaxo is serious about slimming down in the right places, however, upside for shareholders could be 40% or more.
Consumer Health Business
Glaxo’s joint venture with Novartis will create a consumer health company with £6.5bn of revenues, it was announced earlier this year. The deal is expected to close in the first half of 2015. The British company will retain a 63.5% stake in the venture.
While it appears that structural changes are on the cards, Andrew Witty, Glaxo’s chief executive offer, runs the risk of losing the backing of key shareholders.
In an interview with the Financial Times on 27 July, he hinted at the possibility of spinning off Glaxo’s consumer health-care division from core activities.
“GlaxoSmithKline has no plans to spin off its consumer health-care division, a spokesman said,” Bloomberg reported the following day.
If anything, Glaxo should do a better job in managing expectations. That said, a spin-out of the consumer health business — whose capital requirements for research and development (R&D) are relatively small — may not be the best solution for shareholders. And it may not be the strategy that Mr Witty has in mind right now.
“Well, I never understood why they were in consumer health to start with,” a senior pharma analyst in the City told me. “That’s the obvious thing they could spin out, though they’ve been building it up for a while so it would seem a rather odd move,” he added.
What’s There To Break Up?
Glaxo may break up its operations geographically, although such a strategy would pose serious problems with regard to capital allocation. There’s a better alternative, in my view. Core R&D expenditures stood at £3.4bn in 2013 – some 90% of which were invested in core pharmaceutical activities. The consumer health operations are non-core, and account for roughly 10% of Glaxo’s total R&D investment.
Take Convergence Pharmaceuticals, which was spun out of Glaxo in 2010. It is planning an IPO of up to £100m either in London or in New York. Glaxo retained a minority stake in Convergence, and will benefit if the float is successful. More such deals would make a lot of sense in the next 12 months.
Decisive action is needed. From revenues to earnings, every single P&L item was a big disappointment in the second quarter. The bribery scandal in China is also a big problem, but that’s fully priced into Glaxo shares, in my view.
Operationally, Glaxo isn’t in great shape, as quarterly results showed. Its product pipeline is better than that of AstraZeneca (LSE: AZN) (NYSE: AZN.US), but its existing drugs are faced with fierce competition as cheaper alternatives pose a threat to its market share globally.
Glaxo Vs Astra
Forward trading multiples based on earnings before interest, taxes, depreciation and amortisation in 2014 and 2015 indicate that Glaxo’s shares trade at a discount of between 9% and 16% versus Astra’s.
Glaxo is more profitable than Astra at operating level, though — and is also expected to remain more profitable into 2015. Its net leverage is higher than Astra’s, but is manageable, which signals a more efficient balance sheet. As a result of a better capital structure, Glaxo offers higher returns to shareholders than Astra.
Astra shares still price in an M&A premium in the region of 25%, in my view.
That premium may well be assigned to Glaxo by Pfizer, particularly if Glaxo shows a commitment to shrink direct R&D investments ahead of disposals. Alternatively, a more efficient Glaxo may decide to go for Pfizer, which has lost more than $40bn of market value in less than one year. Then, say in the second half of 2015, Glaxo may even be able to impose its own terms at the negotiating table.
Glaxo shares offer a terrific dividend yield, and should be included in a diversified portfolio, just as our analysts suggest.
http://www.fool.co.uk/investing/2014/08/06/glaxosmithkline-plc-offers-40-upside-for-canny-investors/?source=uhpsithla0000003
By Alessandro Pasetti - Wednesday, 6 August, 2014
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) shares are down 9.6% in 2014. In the last twelve months of trading, they have lost 14.7% of value. If Glaxo is serious about slimming down in the right places, however, upside for shareholders could be 40% or more.
Consumer Health Business
Glaxo’s joint venture with Novartis will create a consumer health company with £6.5bn of revenues, it was announced earlier this year. The deal is expected to close in the first half of 2015. The British company will retain a 63.5% stake in the venture.
While it appears that structural changes are on the cards, Andrew Witty, Glaxo’s chief executive offer, runs the risk of losing the backing of key shareholders.
In an interview with the Financial Times on 27 July, he hinted at the possibility of spinning off Glaxo’s consumer health-care division from core activities.
“GlaxoSmithKline has no plans to spin off its consumer health-care division, a spokesman said,” Bloomberg reported the following day.
If anything, Glaxo should do a better job in managing expectations. That said, a spin-out of the consumer health business — whose capital requirements for research and development (R&D) are relatively small — may not be the best solution for shareholders. And it may not be the strategy that Mr Witty has in mind right now.
“Well, I never understood why they were in consumer health to start with,” a senior pharma analyst in the City told me. “That’s the obvious thing they could spin out, though they’ve been building it up for a while so it would seem a rather odd move,” he added.
What’s There To Break Up?
Glaxo may break up its operations geographically, although such a strategy would pose serious problems with regard to capital allocation. There’s a better alternative, in my view. Core R&D expenditures stood at £3.4bn in 2013 – some 90% of which were invested in core pharmaceutical activities. The consumer health operations are non-core, and account for roughly 10% of Glaxo’s total R&D investment.
Take Convergence Pharmaceuticals, which was spun out of Glaxo in 2010. It is planning an IPO of up to £100m either in London or in New York. Glaxo retained a minority stake in Convergence, and will benefit if the float is successful. More such deals would make a lot of sense in the next 12 months.
Decisive action is needed. From revenues to earnings, every single P&L item was a big disappointment in the second quarter. The bribery scandal in China is also a big problem, but that’s fully priced into Glaxo shares, in my view.
Operationally, Glaxo isn’t in great shape, as quarterly results showed. Its product pipeline is better than that of AstraZeneca (LSE: AZN) (NYSE: AZN.US), but its existing drugs are faced with fierce competition as cheaper alternatives pose a threat to its market share globally.
Glaxo Vs Astra
Forward trading multiples based on earnings before interest, taxes, depreciation and amortisation in 2014 and 2015 indicate that Glaxo’s shares trade at a discount of between 9% and 16% versus Astra’s.
Glaxo is more profitable than Astra at operating level, though — and is also expected to remain more profitable into 2015. Its net leverage is higher than Astra’s, but is manageable, which signals a more efficient balance sheet. As a result of a better capital structure, Glaxo offers higher returns to shareholders than Astra.
Astra shares still price in an M&A premium in the region of 25%, in my view.
That premium may well be assigned to Glaxo by Pfizer, particularly if Glaxo shows a commitment to shrink direct R&D investments ahead of disposals. Alternatively, a more efficient Glaxo may decide to go for Pfizer, which has lost more than $40bn of market value in less than one year. Then, say in the second half of 2015, Glaxo may even be able to impose its own terms at the negotiating table.
Glaxo shares offer a terrific dividend yield, and should be included in a diversified portfolio, just as our analysts suggest.
http://www.fool.co.uk/investing/2014/08/06/glaxosmithkline-plc-offers-40-upside-for-canny-investors/?source=uhpsithla0000003
midknight
- 08 Aug 2014 10:12
- 186 of 290
midknight
- 08 Aug 2014 10:16
- 187 of 290
midknight
- 08 Aug 2014 16:45
- 188 of 290
skinny
- 08 Aug 2014 17:19
- 189 of 290
I think today may have been the day to buy!
skinny
- 12 Aug 2014 06:12
- 190 of 290
midknight
- 12 Aug 2014 10:00
- 191 of 290
skinny
- 13 Aug 2014 15:56
- 192 of 290
I've had a small long here @1,386.00 in the hope that the bottom is in (for now).
midknight
- 13 Aug 2014 16:21
- 193 of 290
You may be right. I did the same last week.
GSK in NY does not seem to be doing much. Been the same for quite a few
days now. Here.
GSK in NY does not seem to be doing much. Been the same for quite a few
days now. Here.
skinny
- 13 Aug 2014 16:31
- 194 of 290
Thanks - I've got it on my NYSE monitor - albeit 15 minutes delayed.
;MA(50);MA(200)&IND=MACD(26,12,9);RSI(14)&Layout=2Line;Default;Price;HisDate&XCycle=&XFormat=)
midknight
- 15 Aug 2014 15:48
- 195 of 290
Aug 15: Credit Suisse: Undderperform - Tp: 1475p
skinny
- 21 Aug 2014 07:19
- 196 of 290
Glaxo Receives US Approval For Asthma Treatment Arnuity Ellipta
LONDON (Alliance News) - GlaxoSmithKline PLC said late Wednesday the US Food and Drug Administration has approved its Arnuity Ellipta treatment for asthma in patients aged 12 years and older.
Arnuity is not indicated for the relief of acute bronchospasm, Glaxo said. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio.
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, senior vice president and head of Glaxo's Global Respiratory Franchise in a statement.
LONDON (Alliance News) - GlaxoSmithKline PLC said late Wednesday the US Food and Drug Administration has approved its Arnuity Ellipta treatment for asthma in patients aged 12 years and older.
Arnuity is not indicated for the relief of acute bronchospasm, Glaxo said. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio.
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, senior vice president and head of Glaxo's Global Respiratory Franchise in a statement.
Greyhound - 21 Aug 2014 07:53 - 197 of 290
A bit of a steal at these levels I reckon.
midknight
- 21 Aug 2014 10:02
- 198 of 290
Aug 21: Deutsche; Hold - TP: 1500p
skinny
- 21 Aug 2014 11:22
- 199 of 290
Just been limited out of half +55p
skinny
- 21 Aug 2014 13:59
- 200 of 290
Just bought them back 11p cheaper.
skinny
- 26 Aug 2014 07:24
- 201 of 290
Triumeq US Approval
London, UK, 22 August, 2014 - ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
more..
London, UK, 22 August, 2014 - ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.
more..
midknight
- 27 Aug 2014 16:05
- 202 of 290
From 1365 intraday low on 8 August to 1462 today... the comeback kid.
skinny
- 27 Aug 2014 16:09
- 203 of 290
Well done Midknight - I bought @1,386, sold half +55 and bought them back 11p lower.
So far, so good.
So far, so good.
skinny
- 28 Aug 2014 12:25
- 205 of 290
Good find Midkinght - shaping up rather well!
skinny
- 03 Sep 2014 14:29
- 206 of 290
Triumeq receives EU approval
GlaxoSmithKline plc (LSE:GSK) today announced that ViiV Healthcare Ltd (a global specialist HIV company with GlaxoSmithKline, Pfizer, Inc. and Shionogi Limited as shareholders) is issuing the following statement today:
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
GlaxoSmithKline plc (LSE:GSK) today announced that ViiV Healthcare Ltd (a global specialist HIV company with GlaxoSmithKline, Pfizer, Inc. and Shionogi Limited as shareholders) is issuing the following statement today:
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
skinny
- 04 Sep 2014 10:49
- 207 of 290
Once this area of noise is behind, hopefully a move to @1540 PDQ.
midknight
- 04 Sep 2014 10:53
- 208 of 290
midknight
- 04 Sep 2014 11:01
- 209 of 290
midknight
- 08 Sep 2014 11:54
- 210 of 290
Sept 8: Credit Suisse: Underperform - TP: 1400p
skinny
- 08 Sep 2014 15:42
- 211 of 290
Publication positive study results mepolizumab
New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma.
Deutsche Bank Hold 1,430.25 1,500.00 1,500.00 Retains
New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma.
Deutsche Bank Hold 1,430.25 1,500.00 1,500.00 Retains
skinny
- 09 Sep 2014 05:47
- 212 of 290
GSK China consumer healthcare unit linked to DOJ probe in 2012
(Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
GSK confirmed it had conducted an investigation into procurement practices in consumer healthcare in China, but said it did not find any "unethical conduct". It said the inquiry was unrelated to a Chinese criminal investigation into corruption in its pharmaceuticals division that was made public last year.
(Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
GSK confirmed it had conducted an investigation into procurement practices in consumer healthcare in China, but said it did not find any "unethical conduct". It said the inquiry was unrelated to a Chinese criminal investigation into corruption in its pharmaceuticals division that was made public last year.
midknight
- 10 Sep 2014 11:30
- 213 of 290
Sept 10: Deutsche; Hold - TP: 1500p - Reiterates.
Seems to be Deutsche's new baby.
Seems to be Deutsche's new baby.
skinny
- 10 Sep 2014 11:31
- 214 of 290
Well I hope they have more success here than with TW.!!
midknight
- 10 Sep 2014 11:32
- 215 of 290
They seem to have gone cold on TW....
midknight
- 11 Sep 2014 09:39
- 216 of 290
Sept 11;
Berenberg; Hold - TP: 1575p
JP Morgan: Neutral - No TP
Berenberg; Hold - TP: 1575p
JP Morgan: Neutral - No TP
skinny
- 11 Sep 2014 10:00
- 217 of 290
Their last TP was £17 on 17 June, so I guess that still stands.
midknight
- 12 Sep 2014 11:13
- 218 of 290
Yesterday's JPMorgan TP was 1446p.
skinny
- 12 Sep 2014 11:18
- 219 of 290
Midknight - their last TP on 17 Jun was £17 - GSK Broker notes
midknight
- 12 Sep 2014 11:45
- 220 of 290
Skinny, if interested you can get a daily email update re brokers' forecasts for all stocks
here. I never give my name or anything personal. Just email address.
here. I never give my name or anything personal. Just email address.
skinny
- 12 Sep 2014 11:54
- 221 of 290
Thanks Midknight - I've had a look but can't see a JPM TP of 1446p?
skinny
- 12 Sep 2014 12:28
- 223 of 290
Ok thanks - obviously conflicting data!
midknight
- 12 Sep 2014 12:36
- 224 of 290
From the Digital page, it seems there may have been a JPM forecast
after 17 June as well, as the TP is given as unchanged from the previous 1446p TP
given there.
after 17 June as well, as the TP is given as unchanged from the previous 1446p TP
given there.
skinny
- 12 Sep 2014 12:49
- 225 of 290
On the LSE site, it shows your figure yesterday, but shows no other JPM update going back til 18th July - so if there was a TP price change, it must have been between 17th June and 17th July.
Anyway a tad frustrating.
Anyway a tad frustrating.
midknight
- 15 Sep 2014 13:56
- 226 of 290
Sept 15: Deutsche: Hold - Reduces TP from 1500p to 1450p.
midknight
- 17 Sep 2014 16:37
- 227 of 290
midknight
- 18 Sep 2014 10:55
- 228 of 290
skinny
- 19 Sep 2014 09:12
- 229 of 290
GSK China Investigation Outcome
GlaxoSmithKline plc (GSK) today announced that the Changsha Intermediate People's Court in Hunan Province, China ruled that GSK China Investment Co. Ltd (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China's Ministry of Public Security in June 2013.
As a result of the Court's verdict, GSKCI will pay a fine of £297 million (3 billion RMB at a currency exchange rate of 10.0980) to the Chinese government. This will be funded through existing cash resources. Associated costs and charges related to restructuring will be included in GSK's third quarter update.
The illegal activities of GSKCI are a clear breach of GSK's governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com).
GSK has co-operated fully with the authorities and has taken steps to comprehensively rectify the issues identified at the operations of GSKCI. This includes fundamentally changing the incentive program for its salesforces (decoupling sales targets from compensation); significantly reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments.
GlaxoSmithKline plc (GSK) today announced that the Changsha Intermediate People's Court in Hunan Province, China ruled that GSK China Investment Co. Ltd (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China's Ministry of Public Security in June 2013.
As a result of the Court's verdict, GSKCI will pay a fine of £297 million (3 billion RMB at a currency exchange rate of 10.0980) to the Chinese government. This will be funded through existing cash resources. Associated costs and charges related to restructuring will be included in GSK's third quarter update.
The illegal activities of GSKCI are a clear breach of GSK's governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com).
GSK has co-operated fully with the authorities and has taken steps to comprehensively rectify the issues identified at the operations of GSKCI. This includes fundamentally changing the incentive program for its salesforces (decoupling sales targets from compensation); significantly reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments.
midknight
- 19 Sep 2014 12:34
- 230 of 290
midknight
- 22 Sep 2014 10:09
- 231 of 290
midknight
- 22 Sep 2014 15:14
- 232 of 290
midknight
- 23 Sep 2014 09:57
- 233 of 290
Sept 23: Credit Suisse: Underperform - TP: 1400p
skinny
- 25 Sep 2014 08:02
- 234 of 290
midknight
- 30 Sep 2014 10:26
- 235 of 290
Sept 30:
Jefferies and Deutsche: Hold - TP; N/A
Numis: Hold - TP: 1600p
Jefferies and Deutsche: Hold - TP; N/A
Numis: Hold - TP: 1600p
midknight
- 07 Oct 2014 16:40
- 236 of 290
Oct 7: Deutsche keeps Hold but reduces TP from 1450p to 1420p.
midknight
- 08 Oct 2014 10:31
- 237 of 290
Late news yesterday: GSK: UAE investigation
dandu71 - 21 Oct 2014 14:14 - 239 of 290
Anyone recommend a good price to get in? Looking very tempting at these levels.
skinny
- 22 Oct 2014 12:03
- 240 of 290
3rd Quarter Results
Summary
· Group turnover £5.6 billion, -3% excluding divestments
- Pharmaceutical and Vaccines sales -3% with strong growth in Emerging Markets, +12%, Japan +6%, ViiV Healthcare +18%, offset by US -10%, and Europe -2%
- Respiratory -8% reflecting significant changes to pricing and volumes for Advair in US; portfolio transition continues with total global respiratory sales expected to return to growth in 2016
- Q3 Consumer Healthcare sales -3%; recovery from supply interruptions on track with full year sales expected to be broadly flat subject to continued progress of supply recovery plan
· Targeted cost reductions and financial efficiencies help deliver Q3 core EPS of 27.9p +5% at CER and excluding divestments
· Continue to expect full year 2014 core EPS to be broadly similar to 2013 (at CER and on ex-divestment basis)
· Proposed 3-part transaction with Novartis on track for completion in H1 2015
- Will significantly strengthen Vaccines and Consumer Healthcare
- New balance for Group across core businesses of Pharmaceuticals, Vaccines and Consumer Healthcare
- Provides greater ability to create and deliver value for shareholders across the Group
· ViiV Healthcare: intention to explore an IPO of a minority shareholding to enhance future strategic flexibility and visibility within the Group
· New restructuring programme to refocus global pharmaceuticals business and cost base following divestment of oncology products and changed US respiratory market dynamics
- Approximately £1 billion annual cost savings to be delivered over 3 years with ~50% expected in 2016. Savings incremental to the existing announced programmes and additional to the benefits expected from the transaction
· R&D pipeline expected to fuel growth of pharmaceuticals business with sustained flow of new products over next 5-10 years
- Multiple phase II/III assets with significant potential, including: mepolizumab (severe asthma), sirukumab (RA), cabotegravir (HIV); losmapimod (ACS); ICS/LAMA/LABA (COPD); '863 (anaemia); '273 (ADA-SCID)
- Early clinical development opportunities include first-in-class molecules in epigenetics targeting oncology and immuno-inflammation (BETi, EZH2 and LSD-1); respiratory (PI3Kδ); cardiovascular diseases (TRPV4) and inflammatory diseases (RIP-1 & 2 kinases)
· Q3 dividend maintained at 19p per share
· FY14 dividend expected to be 80p +3%. 2015 dividend expected to be maintained at same level as 2014 with additional planned return of £4 billion to shareholders via a B-share scheme post completion of transaction
Summary
· Group turnover £5.6 billion, -3% excluding divestments
- Pharmaceutical and Vaccines sales -3% with strong growth in Emerging Markets, +12%, Japan +6%, ViiV Healthcare +18%, offset by US -10%, and Europe -2%
- Respiratory -8% reflecting significant changes to pricing and volumes for Advair in US; portfolio transition continues with total global respiratory sales expected to return to growth in 2016
- Q3 Consumer Healthcare sales -3%; recovery from supply interruptions on track with full year sales expected to be broadly flat subject to continued progress of supply recovery plan
· Targeted cost reductions and financial efficiencies help deliver Q3 core EPS of 27.9p +5% at CER and excluding divestments
· Continue to expect full year 2014 core EPS to be broadly similar to 2013 (at CER and on ex-divestment basis)
· Proposed 3-part transaction with Novartis on track for completion in H1 2015
- Will significantly strengthen Vaccines and Consumer Healthcare
- New balance for Group across core businesses of Pharmaceuticals, Vaccines and Consumer Healthcare
- Provides greater ability to create and deliver value for shareholders across the Group
· ViiV Healthcare: intention to explore an IPO of a minority shareholding to enhance future strategic flexibility and visibility within the Group
· New restructuring programme to refocus global pharmaceuticals business and cost base following divestment of oncology products and changed US respiratory market dynamics
- Approximately £1 billion annual cost savings to be delivered over 3 years with ~50% expected in 2016. Savings incremental to the existing announced programmes and additional to the benefits expected from the transaction
· R&D pipeline expected to fuel growth of pharmaceuticals business with sustained flow of new products over next 5-10 years
- Multiple phase II/III assets with significant potential, including: mepolizumab (severe asthma), sirukumab (RA), cabotegravir (HIV); losmapimod (ACS); ICS/LAMA/LABA (COPD); '863 (anaemia); '273 (ADA-SCID)
- Early clinical development opportunities include first-in-class molecules in epigenetics targeting oncology and immuno-inflammation (BETi, EZH2 and LSD-1); respiratory (PI3Kδ); cardiovascular diseases (TRPV4) and inflammatory diseases (RIP-1 & 2 kinases)
· Q3 dividend maintained at 19p per share
· FY14 dividend expected to be 80p +3%. 2015 dividend expected to be maintained at same level as 2014 with additional planned return of £4 billion to shareholders via a B-share scheme post completion of transaction
midknight
- 22 Oct 2014 14:41
- 241 of 290
Some encouraging signs in today's statement imo.
Oct 22; Panmure Gordon: Hold - TP: down to 1425p from 1600 on 30 Sept.
This being a core high yield holding for me, I tend to look at low sp as an opportunity to add
and think recent sp under 1330, often well under that, was favourable, if holding for the long term.
Oct 22; Panmure Gordon: Hold - TP: down to 1425p from 1600 on 30 Sept.
This being a core high yield holding for me, I tend to look at low sp as an opportunity to add
and think recent sp under 1330, often well under that, was favourable, if holding for the long term.
goldfinger
- 22 Oct 2014 14:42
- 242 of 290
#GlaxoSmithKline advises that its #ebola vaccine should be ready by the close of the year.
midknight
- 22 Oct 2014 14:58
- 243 of 290
HARRYCAT
- 22 Oct 2014 15:51
- 245 of 290
https://www.ig.com/uk/market-insight-videos?bctid=3852337986001&bclid=3671160850001
Worth a quick listen for those interested in GSK.
Worth a quick listen for those interested in GSK.
midknight
- 23 Oct 2014 10:13
- 246 of 290
Oct 23:
Barclays: Overweight - TP: 1600p
Deutsche: Hold - TP: 1390p (down from 1420)
JP Morgan: Neutral - TP N/A
Barclays: Overweight - TP: 1600p
Deutsche: Hold - TP: 1390p (down from 1420)
JP Morgan: Neutral - TP N/A
midknight
- 24 Oct 2014 10:08
- 247 of 290
Oct 24: Liberum Capital: Sell - TP: 1350p.
Not seen a sell note for GSK and such a low TP for a while.
Not seen a sell note for GSK and such a low TP for a while.
midknight
- 28 Oct 2014 10:10
- 248 of 290
Oct 28: Jefferies: Hold - TP: 1350p
midknight
- 07 Nov 2014 12:07
- 249 of 290
Nov 7; Berenberg: Hold - TP: 1540p (down from 15755p).
midknight
- 21 Nov 2014 11:07
- 250 of 290
NOv 21:
Liberum Capital reiterates: Sell - TP: 1350p
r
Although sp on the up lately, quite a few forecasts with low TPs..
Liberum Capital reiterates: Sell - TP: 1350p
r
Although sp on the up lately, quite a few forecasts with low TPs..
midknight
- 24 Nov 2014 10:00
- 251 of 290
midknight
- 25 Nov 2014 10:38
- 252 of 290
Nov 25:
Exane BNP Parisbas: Underperform - TP 1330p
Exane BNP Parisbas: Underperform - TP 1330p
midknight
- 03 Dec 2014 11:41
- 253 of 290
Dec 3: Morgan Stanley; Overweight - TP: 1700p retained.
midknight
- 09 Dec 2014 11:50
- 254 of 290
Dec 9:
Bank of America: Underperform - TP: 1450p
JP Morgan: Neutral - TP: 1350p
Bank of America: Underperform - TP: 1450p
JP Morgan: Neutral - TP: 1350p
midknight
- 05 Jan 2015 10:10
- 255 of 290
Jan 5: JP Morgan: Underweight - New TP: 1300p (down from 1350p)
midknight
- 15 Jan 2015 10:16
- 256 of 290
Jan 15:
Deutsche Bank: Hold - TP: 1300p
Jefferies: Hold - TP: 1350p
Deutsche Bank: Hold - TP: 1300p
Jefferies: Hold - TP: 1350p
midknight
- 21 Jan 2015 12:12
- 257 of 290
Jan 21: Credit Suisse: Underperform - TP: 1330p
midknight
- 23 Jan 2015 10:14
- 258 of 290
Jan 23: Berenberg: Hold - TP: 1620p
midknight
- 23 Jan 2015 13:29
- 259 of 290
Jan 23: Credit Suisse reiterates: Underperform and retains 1330p TP.
midknight
- 23 Jan 2015 13:41
- 260 of 290
midknight
- 05 Feb 2015 10:23
- 262 of 290
Feb 5:
Credit Suisse : Underperform - TP: 1330p
Barclays: Overweight - TP: N/A
Deutsche Bank : Hold - TP: 1300p
JP Morgan... Underweight - TP: N/A
Credit Suisse : Underperform - TP: 1330p
Barclays: Overweight - TP: N/A
Deutsche Bank : Hold - TP: 1300p
JP Morgan... Underweight - TP: N/A
midknight
- 06 Feb 2015 10:20
- 263 of 290
Feb 6:
Liberum Capital: Sell - TP: N/A
Panmure Gordon: Hold - TP: 1425p
Liberum Capital: Sell - TP: N/A
Panmure Gordon: Hold - TP: 1425p
midknight
- 09 Feb 2015 10:29
- 264 of 290
Feb 9:
Liberum Capital : Sell - TP: 1350p
Beaufort Securities: Buy - TP: N/A
Liberum Capital : Sell - TP: 1350p
Beaufort Securities: Buy - TP: N/A
skinny
- 09 Feb 2015 10:34
- 265 of 290
midknight
- 10 Feb 2015 10:04
- 266 of 290
Feb 10: JP Morgan; Underweight - TP: 1250p
midknight
- 13 Feb 2015 10:40
- 267 of 290
Feb 13: Barclays: Overweight: - TP: 1690p
midknight
- 13 Feb 2015 12:07
- 268 of 290
Feb 13: Hold - TP: 1560p
midknight
- 20 Feb 2015 09:52
- 269 of 290
Feb 20: Jefferies: Hold - TP: 1420p
skinny
- 29 Mar 2015 09:56
- 270 of 290
midknight
- 01 Apr 2015 13:08
- 271 of 290
Apr 1: Barclays reiterates: Overweight - TP up frpm 1690p to 1840p
midknight
- 07 Apr 2015 11:54
- 272 of 290
Apr 7: Credit Suisse: Underperform - TP: 1440p
midknight
- 08 Apr 2015 10:15
- 273 of 290
Apr 8: Deutsche Bank: Ho;d - TP: 1600p
midknight
- 13 Apr 2015 10:04
- 274 of 290
Apr 13: Jefferies: Hold - TP: 1520p
midknight
- 16 Apr 2015 10:15
- 275 of 290
Apr 16:
Barclays: Overweight - TP: 1840pt
Credit Suisse: Underperform - TP: 1440p
Barclays: Overweight - TP: 1840pt
Credit Suisse: Underperform - TP: 1440p
midknight
- 17 Apr 2015 13:23
- 276 of 290
Apr 17; Societe Generale: Sell - TP: 1550p
midknight
- 22 Apr 2015 10:06
- 277 of 290
Apr 22:
JP Morgan: Underweight - TP: 1380p
Liberum Capital: Sell - TP: 1400p
JP Morgan: Underweight - TP: 1380p
Liberum Capital: Sell - TP: 1400p
midknight
- 07 May 2015 09:57
- 278 of 290
May 7:
Liberum Capital: Sell - TP: 1400p
Societe Generale: Sell - TP: 1550p
JP Morgan: Underweight
Deutsche Bank: Hold: TP: 1600p
Liberum Capital: Sell - TP: 1400p
Societe Generale: Sell - TP: 1550p
JP Morgan: Underweight
Deutsche Bank: Hold: TP: 1600p
midknight
- 21 May 2015 10:09
- 279 of 290
May 21:
Citigroup: Neutral - TP: 1550p
Jefferies: Hold - TP: 1450p
Citigroup: Neutral - TP: 1550p
Jefferies: Hold - TP: 1450p
midknight
- 26 May 2015 10:43
- 280 of 290
May 26: JP Morgan: Underweight and reduces TP to 1320p
midknight
- 12 Jun 2015 10:45
- 281 of 290
June 12:
Barclays.: Overweight - TP: 1820p
Kepler Cheuvreux: Hold - TP: 1540p
Barclays.: Overweight - TP: 1820p
Kepler Cheuvreux: Hold - TP: 1540p
midknight
- 23 Jun 2015 10:29
- 282 of 290
cynic
- 23 Jun 2015 11:01
- 283 of 290
haven't really investigated, but GSK looks ridiculous value, especially if it has a good divi, which i think it does
HARRYCAT
- 23 Jun 2015 11:42
- 284 of 290
Divi yield approx 5.8% at present.
midknight
- 26 Jun 2015 11:16
- 285 of 290
June 26: HSBC; Buy - TP: 1700p (New coverage)
cynic
- 26 Jun 2015 11:34
- 286 of 290
i'ld be very happy indeed that with that or even 30 bob less :-)
midknight
- 13 Jul 2015 09:49
- 287 of 290
July 13: Jefferies: Hold - TP: 1350p
midknight
- 14 Jul 2015 10:00
- 288 of 290
July 14: Barclays: Overweight - TP: 1650p
midknight
- 29 Jul 2015 12:16
- 289 of 290
GSK delivers Q2 Group sales of £5.9 billion +7% CER and
core EPS of 17.3p (flat CER) in first full quarter of performance
since transaction.
Half-yearly financial report
core EPS of 17.3p (flat CER) in first full quarter of performance
since transaction.
Half-yearly financial report
midknight
- 18 Aug 2015 10:13
- 290 of 290
Aug 18:
Credit Suisse: Underperform - TP: 1440p
JP Morgan: Underweight - TP: 1320p
Credit Suisse: Underperform - TP: 1440p
JP Morgan: Underweight - TP: 1320p
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter